



Cochrane Database of Systematic Reviews
 
Avatar Therapy for people with schizophrenia or related disorders
(Review)
 
  Aali G, Kariotis T, Shokraneh F  
  Aali G, Kariotis T, Shokraneh F. 
Avatar Therapy for people with schizophrenia or related disorders. 




Avatar Therapy for people with schizophrenia or related disorders (Review)
 








Cochrane Database of Systematic Reviews
T A B L E   O F   C O N T E N T S
HEADER......................................................................................................................................................................................................... 1
ABSTRACT..................................................................................................................................................................................................... 1
PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2












CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 27
DATA AND ANALYSES.................................................................................................................................................................................... 34
Analysis 1.1. Comparison 1: Avatar therapy versus treatment as usual, Outcome 1: Mental state: 1a. Specific – positive – average
endpoint score (PANSS-P, high = poor) – short term..........................................................................................................................
36
Analysis 1.2. Comparison 1: Avatar therapy versus treatment as usual, Outcome 2: Mental state: 1b. Specific – insight – average
endpoint score (BAVQ-R attitude to voices, high = poor) – short term.............................................................................................
36
Analysis 1.3. Comparison 1: Avatar therapy versus treatment as usual, Outcome 3: Mental state: 1c. Specific – insight – average
endpoint score (BAVQ-R attitude to voices, high = poor, skewed data) – short term.......................................................................
36
Analysis 1.4. Comparison 1: Avatar therapy versus treatment as usual, Outcome 4: Mental state: 1d. Specific – depression –
average endpoint score (various scales, high = poor, skewed data – short term.............................................................................
36
Analysis 1.5. Comparison 1: Avatar therapy versus treatment as usual, Outcome 5: Mental state: 1e. Specific – negative – average
endpoint score (PANSS-N, high = poor) – short term.........................................................................................................................
37
Analysis 1.6. Comparison 1: Avatar therapy versus treatment as usual, Outcome 6: Mental state: 2a. General – total – average
endpoint score (PANSS total, high = poor) – short term)...................................................................................................................
37
Analysis 1.7. Comparison 1: Avatar therapy versus treatment as usual, Outcome 7: Mental state: 2b. General – total – average
endpoint score ( PSYRATS total, high = poor) – short term................................................................................................................
37
Analysis 1.8. Comparison 1: Avatar therapy versus treatment as usual, Outcome 8: Mental state: 2c. General – total – average
endpoint score (PSRS, high poor, skewed data) – short term...........................................................................................................
37
Analysis 1.9. Comparison 1: Avatar therapy versus treatment as usual, Outcome 9: Global state: 1. Any change – needing
counselling and support – short term.................................................................................................................................................
38
Analysis 1.10. Comparison 1: Avatar therapy versus treatment as usual, Outcome 10: Global state: 2. Relapse (rehospitalised)
– short term...........................................................................................................................................................................................
38
Analysis 1.11. Comparison 1: Avatar therapy versus treatment as usual, Outcome 11: Leaving study early: 1. For any reason –
short term..............................................................................................................................................................................................
38
Analysis 1.12. Comparison 1: Avatar therapy versus treatment as usual, Outcome 12: Leaving study early: 2. For specific reason
– short term...........................................................................................................................................................................................
39
Analysis 1.13. Comparison 1: Avatar therapy versus treatment as usual, Outcome 13: Adverse eHects: anxiety – short term........ 39
Analysis 1.14. Comparison 1: Avatar therapy versus treatment as usual, Outcome 14: Quality of life: average endpoint score
(QLESQ-SF, high = good) – short term.................................................................................................................................................
39
Analysis 2.1. Comparison 2: Avatar therapy versus supportive counselling, Outcome 1: Mental state: 1a. Specific – positive –
average endpoint score (SAPS, high = poor, skewed data) – short term..........................................................................................
41
Analysis 2.2. Comparison 2: Avatar therapy versus supportive counselling, Outcome 2: Mental state: 1b. Specific – insight –
average endpoint score (various scales, high = poor) – short term...................................................................................................
41
Analysis 2.3. Comparison 2: Avatar therapy versus supportive counselling, Outcome 3: Mental state: 1c. Specific – depression –
average endpoint score (various scales, high = poor, skewed data) – short term............................................................................
41
Analysis 2.4. Comparison 2: Avatar therapy versus supportive counselling, Outcome 4: Mental state: 1d. Specific – negative –
average endpoint score (SANS, high = good, skewed data) – short term.........................................................................................
42
Analysis 2.5. Comparison 2: Avatar therapy versus supportive counselling, Outcome 5: Mental state: 2a. General – average
endpoint score ( PSYRATS total, high = poor) – short term................................................................................................................
42
Avatar Therapy for people with schizophrenia or related disorders (Review)









Cochrane Database of Systematic Reviews
Analysis 2.6. Comparison 2: Avatar therapy versus supportive counselling, Outcome 6: Leaving study early: 1a. For any reason
– short term...........................................................................................................................................................................................
42
Analysis 2.7. Comparison 2: Avatar therapy versus supportive counselling, Outcome 7: Leaving study early: 1b. For specific
reason – short term..............................................................................................................................................................................
43
Analysis 2.8. Comparison 2: Avatar therapy versus supportive counselling, Outcome 8: Quality of life: average endpoint score




CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 45
DECLARATIONS OF INTEREST..................................................................................................................................................................... 45
SOURCES OF SUPPORT............................................................................................................................................................................... 45
DIFFERENCES BETWEEN PROTOCOL AND REVIEW.................................................................................................................................... 45
Avatar Therapy for people with schizophrenia or related disorders (Review)









Cochrane Database of Systematic Reviews
[Intervention Review]
Avatar Therapy for people with schizophrenia or related disorders
Ghazaleh Aali1, Timothy Kariotis2, Farhad Shokraneh3
1Cochrane Schizophrenia Group, Institute of Mental Health, The University of Nottingham, Nottingham, UK. 2School of Computing and
Information Systems, University of Melbourne, Parkville, Melbourne, Australia. 3Cochrane Schizophrenia Group, Institute of Mental
Health, Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK
Contact address: Ghazaleh Aali, ghazaleh.aali@nottingham.ac.uk.
Editorial group: Cochrane Schizophrenia Group.
Publication status and date: New, published in Issue 5, 2020.
Citation: Aali G, Kariotis T, Shokraneh F. Avatar Therapy for people with schizophrenia or related disorders. Cochrane Database of
Systematic Reviews 2020, Issue 5. Art. No.: CD011898. DOI: 10.1002/14651858.CD011898.pub2.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Many people with schizophrenia do not achieve satisfactory improvements in their mental state, particularly the symptom of hearing voices
(hallucinations), with medical treatment.
Objectives
To examine the eHects of Avatar Therapy for people with schizophrenia or related disorders.
Search methods
In December 2016, November 2018 and April 2019, the Cochrane Schizophrenia Group's Study-Based Register of Trials (including registries
of clinical trials) was searched, review authors checked references of all identified relevant reports to identify more studies and contacted
authors of trials for additional information.
Selection criteria
All randomised clinical trials focusing on Avatar Therapy for people with schizophrenia or related disorders.
Data collection and analysis
We extracted data independently. For binary outcomes, we calculated risk ratio (RR) and 95% confidence intervals (CI), on an intention-to-
treat basis. For continuous data, we estimated the mean diHerence (MD) between groups and 95% CIs. We employed a fixed-eHect model
for analyses. We assessed risk of bias for included studies and created 'Summary of findings' tables using GRADE. Our main outcomes of
interest were clinically important change in; mental state, insight, global state, quality of life and functioning as well as adverse eHects
and leaving the study early.
Main results
We found 14 potentially relevant references for three studies (participants = 195) comparing Avatar Therapy with two other interventions;
treatment as usual or supportive counselling. Both Avatar Therapy and supportive counselling were given in addition (add-on) to the
participants' normal care. All of the studies had high risk of bias across one or more domains for methodology and, for other risks of bias,
authors from one of the studies were involved in the development of the avatar systems on trial and in another trial, authors had patents
on the avatar system pending.
1. Avatar Therapy compared with treatment as usual
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When Avatar Therapy was compared with treatment as usual average endpoint Positive and Negative Syndrome Scale – Positive (PANSS-
P) scores were not diHerent between treatment groups (MD –1.93, 95% CI –5.10 to 1.24; studies = 1, participants = 19; very low-certainty
evidence). A measure of insight (Revised Beliefs about Voices Questionnaire; BAVQ-R) showed an eHect in favour of Avatar Therapy (MD –
5.97, 95% CI –10.98 to –0.96; studies = 1, participants = 19; very low-certainty evidence). No one was rehospitalised in either group in the
short term (risk diHerence (RD) 0.00, 95% CI –0.20 to 0.20; studies = 1, participants = 19; low-certainty evidence). Numbers leaving the study
early from each group were not clearly diHerent – although more did leave from the Avatar Therapy group (6/14 versus 0/12; RR 11.27,
95% CI 0.70 to 181.41; studies = 1, participants = 26; low-certainty evidence). There was no clear diHerence in anxiety between treatment
groups (RR 5.54, 95% CI 0.34 to 89.80; studies = 1, participants = 19; low-certainty evidence). For quality of life, average Quality of Life
Enjoyment and Satisfaction Questionnaire-Short Form (QLESQ-SF) scores favoured Avatar Therapy (MD 9.99, 95% CI 3.89 to 16.09; studies
= 1, participants = 19; very low-certainty evidence). No study reported data for functioning.
2. Avatar Therapy compared with supportive counselling
When Avatar Therapy was compared with supportive counselling (all short-term), general mental state (Psychotic Symptom Rating Scale
(PSYRATS)) scores favoured the Avatar Therapy group (MD –4.74, 95% CI –8.01 to –1.47; studies = 1, participants = 124; low-certainty
evidence). For insight (BAVQ-R), there was a small eHect in favour of Avatar Therapy (MD –8.39, 95% CI –14.31 to –2.47; studies = 1,
participants = 124; low-certainty evidence). Around 20% of each group leO the study early (risk ratio (RR) 1.06, 95% CI 0.59 to 1.89; studies
= 1, participants = 150; moderate-certainty evidence). Analysis of quality of life scores (Manchester Short Assessment of Quality of Life
(MANSA)) showed no clear diHerence between groups (MD 2.69, 95% CI –1.48 to 6.86; studies = 1, participants = 120; low-certainty evidence).
No data were available for rehospitalisation rates, adverse events or functioning.
Authors' conclusions
Our analyses of available data shows few, if any, consistent eHects of Avatar Therapy for people living with schizophrenia who experience
auditory hallucinations. Where there are eHects, or suggestions of eHects, we are uncertain because of their risk of bias and their unclear
clinical meaning. The theory behind Avatar Therapy is compelling but the practice needs testing in large, long, well-designed, well-reported
randomised trials undertaken with help from – but not under the direction of – Avatar Therapy pioneers.
P L A I N   L A N G U A G E   S U M M A R Y
Avatar Therapy for schizophrenia or related disorders
Review question
Is Avatar Therapy an eHective add-on treatment for people with schizophrenia and schizoaHective disorder?
Background
Auditory hallucination is perceiving voices when there is no external stimulus. Around 70% of people with schizophrenia experience these.
Medication may help cause these to decrease or disappear. However, some people do not want to take medication and, in a proportion
of people, it has little meaningful eHect. Avatar Therapy is an experimental technology that uses a visualised avatar face, voice and other
sensory input to create an interactive computerised environment. We investigated the eHects of Avatar Therapy for improving auditory
hallucinations for people with schizophrenia.
Searches
Cochrane Schizophrenia's Information Specialist searched through the Cochrane Schizophrenia Group's database for randomised trials
(clinical studies where people are randomly put into one of two or more treatment groups) of people with schizophrenia receiving either
Avatar Therapy or treatment as usual. We found 14 reports from four studies.
The evidence is current to April 2020.
Trials
Four studies met our inclusion criteria, three of which provided useable data and one is still underway. The reliability of the evidence for
the three included studies was very low to low. All data were limited to six weeks' treatment and one week' follow-up and, in some cases,
data were not usable (we contacted the authors). All the reported data are just for the short-term period of trials and it is apparent that we
need more studies with medium- to long-term periods to be able to estimate the rate of Avatar Therapy's eHectiveness.
Conclusions
Three short-term studies with 195 participants were included in this review. Avatar Therapy was compared with treatment as usual and
supportive counselling. Evidence from the trials was not high quality. Although there were some suggestions of positive eHects, because of
the unclear meaning for front-line care, and the considerable risk of bias of each of the results, we cannot be certain of these eHects. There
is just as great a risk of Avatar Therapy causing problems to people. More trials are needed, and those undertaking them should collaborate,
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work with all involved to choose outcomes that mean something in daily life, and design studies that will provide clear information across
months to years for anyone who is interested.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Avatar Therapy compared to treatment as usual (all short-term) for schizophrenia or related disorders
Avatar Therapy compared to treatment as usual (all short-term) for schizophrenia or related disorders
Patient or population: schizophrenia or related disorders
Setting:
Intervention: Avatar Therapy
Comparison: treatment as usual (all short-term)



















Mental state*: specific – positive – average
endpoint score (PANSS-P, high = poor) – short
term
— MD 1.93 lower (5.10





This was the nearest proxy
measure for our prestated
binary outcome, clinically
important change in mental
state.
Mental state: specific – insight – average at-
titude to voices score (BAVQ-R, high = poor) –
short term
— MD 5.97 lower






This was the nearest proxy
measure for our prestated
binary outcome, clinically
important change in insight.
Global state: relapse (rehospitalised) –
short term








RD reported as no-one in ei-
ther group was hospitalised.









Avatar Therapy likely results
in little to no difference for
the outcome of 'leaving
study early for any reason'.
Adverse events – anxiety – after first session
– short term



















































































































































Quality of life: average endpoint score
(QLESQ-SF, high = good) – short term
— MD 9.99 higher






This was the nearest proxy
measure for our prestated
binary outcome, clinically
important change in quality
of life.
Functioning: clinically important change See comment See comment — (0 studies) — No study reported on this
important outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
BAVQ-R: Revised Beliefs about Voices Questionnaire; CI: confidence interval; MD: mean difference; PANSS-P: Positive and Negative Syndrome Scale – Positive; QLESQ-SF:
Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; RCT: randomised controlled trial; RD: risk difference; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aRisk of bias: 'serious' (downgraded one level) – poor reporting of randomisation, no substantive discussion of any blinding or consideration of blinding. Authors contacted but
limited information available.
bIndirectness: 'serious' (downgraded one level) – proxy scale for binary outcome prestated in protocol.
cImprecision: 'serious' (downgraded one level) – wide confidence intervals generated by very small study.
 
 
Summary of findings 2.   Avatar Therapy compared to supportive counselling (all short-term) for schizophrenia or related disorders
Avatar therapy compared to supportive counselling (all short-term) for schizophrenia or related disorders
Patient or population: schizophrenia or related disorders
Setting:
Intervention: Avatar Therapy































































































































































Mental state*: general – average
endpoint score (PSYRATS, high =
poor)







This was the nearest proxy measure for our
prestated binary outcome, clinically impor-
tant change in positive symptoms. Avatar
Therapy may reduce mental state scores
slightly but it is unclear how these ratings re-
late to everyday life and functioning.
Mental state: specific – insight
– average attitude to voices score
(BAVQ-R, high = poor) – short
term







Avatar Therapy likely results in a little differ-
ence in a measure of insight (average attitude
to voices score (BAVQ-R, high score = poor)).
This was the nearest proxy measure for our
prestated binary outcome, clinically impor-
tant change in insight. We are unclear of the
clinical meaning of this measure.
Global state: relapse (rehospi-
talised)
See comment See comment — (0 studies) — No study reported on this important out-
come.
Leaving study early: for any rea-
son – short term








Avatar Therapy results in little to no differ-
ence in leaving study early (any reason by up
to 6 months).
Adverse events – anxiety – after
first session
See comment See comment — (0 studies) — No study reported on this important out-
come.
Quality of life: average end-
point score (MANSA, high = good)
– short term







Avatar Therapy likely results in little to no
difference in quality of life – as measured by
MANSA. This was the nearest proxy measure
for our prestated binary outcome, clinically
important change in quality of life.
Functioning: clinically important
change
See comment See comment — (0 studies) — No study reported on this important out-
come.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
BAVQ-R: Revised Beliefs about Voices Questionnaire; CI: confidence interval; MANSA: Manchester Short Assessment of Quality of Life; MD: mean difference; PSYRATS: Psy-
chotic Symptom Rating Scale; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence











































































































































Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aIndirectness: 'serious' (downgraded one level) – proxy scale for binary outcome prestated in protocol.
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B A C K G R O U N D
Description of the condition
Schizophrenia is a persistent, relapsing and disabling mental
disorder that has a global prevalence between 0.4% and 0.7%
(Saha 2005). This serious mental illness is characterised by
1. positive symptoms, such as perceptions with no cause
(hallucinations) or false beliefs (delusions), or both; and 2. negative
symptoms which include catatonic signs, disorganised thoughts
and behaviour, apathy and lack of motivation (Carpenter 1994).
Hearing voices (auditory hallucinations) is a common symptom of
schizophrenia, which is oOen treatment-resistant. For those people
with schizophrenia who suHer from hearing one or more voices,
around 70% of people with schizophrenia experience these (Comer
2017), and 30% will have auditory hallucinations that are not
alleviated by taking medication (Kane 1996).
Description of the intervention
Antipsychotic medications are the main line of treatment for
schizophrenia; however, some of the symptoms of schizophrenia,
such as auditory hallucinations, are treatment-resistant (Kane
1996). Non-pharmaceutical psychotherapeutic interventions such
as cognitive behavioural therapy (CBT) are oOen suggested as
additional treatments. However, CBT's eHect size for treating
the positive symptoms is small, and its eHect on relapse and
the negative symptoms of schizophrenia has not been proved
(McKenna 2014).
Virtual reality has also been used for people with schizophrenia
for social skills training, to improve thinking and understanding
processes, and for treatment support (Kip 2019); however, Avatar
Therapy is a relatively recently suggested treatment which could
be used as an adjunct to the usual antipsychotic treatment,
particularly for treatment-resistant auditory hallucinations (LeH
2013).
Avatar Therapy has been suggested for people who experience
distressing voices, hypothesising that it could reduce the
severity and rate of auditory hallucinations (Huckvale 2013;
ISRCTN65314790 2013). During the therapy, a psychiatrist assists
the patient to create an avatar, an audio-visual entity, using
a computer program. This avatar is modified so that its
characteristics match the voices that bother the patient (LeH
2013). Then the therapist uses this avatar to talk back to the
patient in therapy sessions and they can exercise taught methods
to cope with the voices. While the person with schizophrenia is
encouraged to establish dialogues with the avatar and be resistant
to the hallucination, the therapist then manages the avatar so it is
gradually controlled by the patient and the avatar’s mode changes
from persecutory to supportive during the therapy sessions (LeH
2013). Audio recordings of all sessions are made so that the patient
can listen to them at home using an MP3 Player (Rus-Calafell
2014). The studies have cited LeH 2013 as the first trial; however,
it is unclear if the other studies used the same Avatar Therapy
intervention design or made their own intervention.
How the intervention might work
One of the main aspects people with schizophrenia describe about
their auditory hallucinations is that they oOen feel helpless in
coping with the voices (LeH 2013). Interacting with the hallucination
may help people with schizophrenia. It has been reported that
people with schizophrenia who are able to talk back to the voices
could have more control over the voices (Nayani 1996); and their
suHering gradually is reduced (LeH 2013). However, interacting with
a hallucination involves interacting with an invisible character and
can be diHicult because of lack of mutual interaction and body/face
language. Many people with schizophrenia oOen imagine a voice-
associated face when hearing a hallucination, but cannot see the
face to interact with it. An avatar is both an audio (voice) and a visual
(face) entity, and can be used as an audio-visual interface between
the hallucination and the patient to facilitate the establishment
of a conversation between patient and the voice (LeH 2013). Also,
there might be other advantages in talking to an avatar; first, Avatar
Therapy sessions can be recorded and taken home with the patient
to use when needed – a psychiatrist is unlikely to be available at
all times and places; second, an avatar's voice can be made to
be very similar to the hallucination the patient hears; an avatar's
voice might help people with schizophrenia to practise how to take
control of voices.
Why it is important to do this review
There is currently no systematic review of Avatar Therapy for
treatment-resistant auditory hallucinations among people with
schizophrenia. We aimed to examine whether Avatar Therapy
could have a therapeutic eHect on auditory hallucinations in
people with schizophrenia. In addition, since there are primary
studies to be systematically reviewed to meet our aim and
Avatar Therapy is a new treatment, this review found and
synthesised the relevant studies on the eHects of Avatar Therapy
for people with schizophrenia who experience treatment-resistant
auditory hallucinations so as to provide clinically useful evidence
for informed decision-making among clinicians, people with
schizophrenia and health policy makers.
O B J E C T I V E S
To examine the eHects of Avatar Therapy for people with
schizophrenia or related disorders.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials; if a trial was described
as 'double blind' but implied randomisation, we included such
trials in a sensitivity analysis (see Sensitivity analysis). If their
inclusion did not result in a substantive diHerence, they remained
in the analyses. If their inclusion resulted in important clinically
significant but not necessarily statistically significant diHerences,
we did not add the data from these lower-quality studies to
the results of the better trials, but presented such data within
a subcategory. We found no quasi-randomised studies, such as
those allocating by alternate days of the week to exclude. Where
people were given additional treatments within Avatar Therapy, we
only included data if the adjunct treatment was evenly distributed
between groups and it was only the Avatar Therapy that was
randomised.
Types of participants
Patients, however defined, with schizophrenia or related disorders,
including schizophreniform disorder, schizoaHective disorder and
Avatar Therapy for people with schizophrenia or related disorders (Review)
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delusional disorder, again, by any means of diagnosis, of any age,
gender or ethnicity.
We were interested in ensuring that information was as relevant
to the current care of people with schizophrenia as possible
so propose to clearly highlight the current clinical state (acute,
early postacute, partial remission, remission) as well as the stage
(prodromal, first episode, early illness, persistent) and as to
whether the studies primarily focused on people with particular
problems (e.g. negative symptoms, treatment-resistant illnesses).
Types of interventions
1. Avatar Therapy
An avatar is a computer-generated audio-visual character utilised
to establish a conversation between the person with schizophrenia
and the voices that person hears, to cope with the voices.
We assessed all the randomised controlled trials in which Avatar
Therapy was one of the study arms either alone or in combination
with other interventions. Avatar Therapy is an adjunctive treatment
for 'treatment as usual'.
2. Control interventions
Any other add-on (to the participants usual care) intervention or
treatment as usual.
3. Supportive counselling
Any face-to-face supportive counselling approach.
Types of outcome measures
We divided all outcomes into short term (less than six months),
medium term (six to 12 months) and long term (over 12 months).
We sought to report binary outcomes recording clear and clinically
meaningful degrees of change (e.g. global impression of much
improved, or more than 50% improvement on a rating scale defined
within the trials). ThereaOer, we listed other binary outcomes and
then those that were continuous. See DiHerences between protocol
and review.
Primary outcomes
1. Mental state – specific (positive – e.g. auditory hallucinations,
delusions)
1.1. Clinically important change in positive symptoms
2. Mental state – specific (insight)
2.1. Clinically important change in insight
3. Adverse e9ects




1.1.1. Clinically important change in specific symptoms (other than
positive)
1.1.2. Any change in specific symptoms
1.1.3. Average endpoint or change score on specific mental state
scale
1.2 General
1.2.1. Clinically important change in general mental state
1.2.2. Any change in general mental state
1.2.3. Average endpoint or change score on general mental state
scale
2. Global state
2.1. Clinically important change in global state
2.2. Any change in global state
2.3. Relapse (including rehospitalisation)
2.4. Average endpoint or change score on global state scale
3. Leaving the study early
3.1. For any reason.
3.2. For specific reason
4. Adverse e9ects
4.1. Clinically important adverse eHects
4.2. Any adverse eHect
4.3. Any change in specific adverse eHects
5. Quality of life
5.1. Clinically important change in quality of life
5.2. Any change in quality of life
5.3. Average endpoint or change score on quality of life scale
6. Functioning
6.1. Clinically important change in functioning
6.2. Any change in functioning
6.3. Average endpoint or change score on functioning scale
'Summary of findings' table
We used the GRADE approach to interpret findings (Schünemann
2011); and used GRADE profiler (GRADEpro; tech.cochrane.org/
revman/gradepro) to import data from Review Manager 5
(tech.cochrane.org/revman) to create 'Summary of findings' tables.
These tables provide outcome-specific information concerning
the overall certainty of the evidence from each included study
in the comparison, the magnitude of eHect of the interventions
examined, and the sum of available data on all primary outcomes
and on selected secondary outcomes. This summary guided our
conclusions and recommendations. We selected the following
main (short term) outcomes for inclusion in the 'Summary of
findings' table:
1. Mental state: clinically important change in positive symptoms
(e.g. auditory hallucinations, delusions)
2. Mental state: insight: clinically important change in insight.
3. Adverse eHects: at least one important adverse eHect.
4. Global state: clinically important change in global state.
5. Leaving the study early: for any reason.
6. Quality of life: clinically important change in quality of life.
7. Functioning: clinically important change in functioning.
If data were not available for these prespecified outcomes but
were available for ones that were similar, we presented the closest
outcome available, but considered this when grading the finding.
Avatar Therapy for people with schizophrenia or related disorders (Review)









Cochrane Database of Systematic Reviews
Search methods for identification of studies
Electronic searches
1. Cochrane Schizophrenia Group's Study-Based Register of
Trials
On 8 December 2016, 9 November 2018 and 14 April 2020, the
information specialist searched the register using the following
search strategy:
(*Avatar Therapy*) in Intervention Field of STUDY
In such a study-based register, searching the major concept
retrieves all the synonyms and relevant studies because all the
studies have already been organised based on their interventions
and linked to the relevant topics (Shokraneh 2017; Shokraneh
2019).
This register is compiled by systematic searches of major resources
(AMED, BIOSIS, CENTRAL, CINAHL, ClinicalTrials.Gov, Embase,
MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly
updates; ProQuest Dissertations and Theses A&I and its quarterly
update; Chinese databases (CBM, CNKI, and Wanfang) and their
annual updates; handsearches; grey literature and conference
proceedings (see Group's website; schizophrenia.cochrane.org/
register-trials). There is no language, date, document type, or




We inspected references of all included studies for further relevant
studies (Figure 1).
 
Figure 1.   Study flow diagram.
Avatar Therapy for people with schizophrenia or related disorders (Review)
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2. Personal contact
We contacted the first author of a study for additional information
regarding non-reported data (NCT03148639). We noted the
outcome of this contact in the Characteristics of included studies
table.
Data collection and analysis
Selection of studies
Review authors (GA, TK and FS) independently inspected
citations from the searches and identified relevant abstracts;
GA independently re-inspected a random 20% sample of these
abstracts to ensure reliability of selection. Where disputes arose,
we acquired the full report for a more detailed scrutiny. Review
authors (GA, TK and FS) then obtained and inspected full reports of
the abstracts or reports meeting the review criteria. GA re-inspected
a random 20% of these full reports to ensure reliability of selection.
Where it was not possible to resolve disagreement by discussion,
we contacted the authors of the study concerned for clarification
(NCT03148639).
Data extraction and management
1. Extraction
Review authors (GA, TK and FS) independently extracted data
from all included studies. In addition, to ensure reliability, GA
independently extracted data from a random sample of these
studies, comprising 10% of the total. We attempted to extract data
presented only in graphs and figures whenever possible, but only
included if two review authors independently obtained the same
result. We contacted authors through an open-ended request in
order to obtain missing information or for clarification whenever
necessary. If studies were multicentre, then, where possible, we
extracted data relevant to each component centre separately.
2. Management
2.1. Forms
We extracted data onto standard, pre-designed, simple forms.
2.2. Scale-derived data
We included continuous data from rating scales only if:
1. the psychometric properties of the measuring instrument had
been described in a peer-reviewed journal (Marshall 2000); and
2. the measuring instrument had not been written or modified by
one of the trialists for that particular trial.
3. the instrument should be a global assessment of an area of
functioning and not sub-scores which are not, in themselves,
validated or shown to be reliable. However, there are exceptions;
we included sub-scores from mental state scales measuring
positive and negative symptoms of schizophrenia.
Ideally, the measuring instrument should either be a self-report or
completed by an independent rater or relative (not the therapist).
We realise that this is not oOen reported clearly: in Description of
studies, we noted if this was the case or not.
2.3. Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. Also, calculation of change needs two assessments
(baseline and endpoint) which can be diHicult in unstable
and diHicult-to-measure conditions such as schizophrenia. We
primarily used endpoint data, and would only use change data if
the former were not available. Endpoint and change data would
combined in the analysis, as we prefer using mean diHerences (MD)
rather than standardised mean diHerences throughout (Higgins
2011).
2.4. Skewed data
Continuous data on clinical and social outcomes are oOen not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we applied the following standards to
all data before inclusion.
For endpoint data:
• When a scale started from the finite number zero, we subtracted
the lowest possible value from the mean, and divided this by
the standard deviation (SD). If this value was lower than one, it
strongly suggested that the data were skewed and we excluded
these data. If this ratio was higher than one but less than two,
there wss suggestion that the data were skewed: we entered
these data and tested whether their inclusion or exclusion would
change the results substantially. Finally, if the ratio was larger
than two, we included these data, because it was less likely that
they were skewed (Altman 1996; Higgins 2011);
• If a scale started from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS), which can have values from
30 to 210 (Kay 1986)), we modified the calculation described
above to take the scale starting point into account. In these
cases, skewed data are present if 2 SD > (S –Smin), where S is the
mean score and Smin is the minimum score.
Please note: we would enter data from studies of at least 200
participants, for example, in the analysis irrespective of the above
rules, because skewed data pose less of a problem in large studies.
We also would have entered change data as when continuous data
were presented on a scale that included a possibility of negative
values (such as change data), if it was diHicult to determine whether
data were skewed or not. We would have presented and entered
change data into statistical analyses.
2.5. Common measurement
To facilitate comparison between trials, we would have converted
variables that were reported in diHerent metrics, such as days in
hospital (mean days per year, per week or per month) to a common
metric (e.g. mean days per month).
2.6. Conversion of continuous to binary
Where possible, we would have converted outcome measures to
dichotomous data. This can be done by identifying cut-oH points
on rating scales and dividing participants accordingly into 'clinically
improved' or 'not clinically improved'. It is generally assumed that
if there is a 50% reduction in a scale-derived score such as the
Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the PANSS
(Kay 1986), this could be considered as a clinically significant
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response (Leucht 2005a; Leucht 2005b). If data based on these
thresholds were not available, we would have used the primary cut-
oH presented by the original authors.
2.7. Direction of graphs
Where possible, we entered data in such a way that the area to
the leO of the line of no eHect indicated a favourable outcome
for Avatar Therapy. Where keeping to this made it impossible to
avoid outcome titles with clumsy double-negatives (e.g. 'not un-
improved'), we reported data where the leO of the line indicated an
unfavourable outcome and noted in the relevant graphs.
Assessment of risk of bias in included studies
Review authors (GA and FS) independently assessed risk of bias
using criteria described in the Cochrane Handbook for Systemic
Reviews of Interventions to assess trial quality (Higgins 2011).
These criteria are based on evidence of associations between
overestimate of eHect and high risk of bias of the article
such as sequence generation, allocation concealment, blinding,
incomplete outcome data and selective reporting, or the way in
which these 'domains' are reported.
If the raters disagreed, the final rating was made by consensus, with
the involvement of another member of the review group. Where
inadequate details of randomisation and other characteristics of
trials were provided, we attempted to contact authors of the studies
to obtain further information. We reported non-concurrence in
quality assessment, but if disputes arose regarding the category to
which a trial was to be allocated, we resolved this by discussion.
We noted the level of risk of bias in the text of the review, 'Risk of
bias' summary (Figure 2), 'Risk of bias' graph (Figure 3), and the
Characteristics of included studies tables. (Figure 2)
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
 
Measures of treatment e9ect
1. Binary data
For binary outcomes, we calculated a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI), as it has been
shown that RR is more intuitive than odds ratios (Boissel 1999); and
that odds ratios tend to be interpreted as RR by clinicians (Deeks
2000). Although the number needed to treat for an additional
beneficial outcome (NNTB) and the number needed to treat for an
additional harmful outcome (NNTH), with their CIs, are intuitively
attractive to clinicians, they are problematic to calculate and
interpret in meta-analyses (Hutton 2009). For binary data presented
in the 'Summary of findings' tables, we, where possible, would have
calculated illustrative comparative risks.
2. Continuous data
For continuous outcomes, we estimated mean diHerence (MD)
between groups, with 95% CIs. We preferred not to calculate eHect
size measures (standardised mean diHerence (SMD)). However, if
scales of very considerable similarity were used, we presumed
there was a small diHerence in measurement, and we calculated
eHect size and transform the eHect back to the units of one or more
of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ 'cluster randomisation' (such as
randomisation by clinician or practice) but analysis and pooling of
clustered data poses problems. First, authors oOen fail to account
for intraclass correlation in clustered studies, leading to a unit-
of-analysis error whereby P values are spuriously low, CIs unduly
narrow and statistical significance overestimated (Divine 1992).
This causes type I errors (Bland 1997; Gulliford 1999).
Where clustering was not accounted for in primary studies, we
presented data in a table, with a (*) symbol to indicate the presence
of a probable unit of analysis error. We sought to contact first
authors of studies to obtain intraclass correlation coeHicients (ICC)
for their clustered data and to adjust for this by using accepted
methods (Gulliford 1999). Where clustering had been incorporated
into the analysis of primary studies, we presented these data as if
from a non-cluster randomised study, but adjust for the clustering
eHect.
We sought statistical advice and have been advised that the binary
data from cluster trials presented in a report should be divided
by a 'design eHect.' This is calculated using the mean number of
participants per cluster (m) and the ICC: thus, design eHect = 1 + (m
– 1) × ICC (Donner 2002). If the ICC was not reported, we assumed it
to be 0.1 (Ukoumunne 1999).
If cluster studies were appropriately analysed taking into account
ICCs and relevant data documented in the report, synthesis with
other studies would have been possible using the generic inverse
variance technique.
2. Cross-over trials
A major concern of cross-over trials was the carry-over eHect.
This occurs if an eHect (e.g. pharmacological, physiological or
psychological) of the treatment in the first phase is carried over to
the second phase. As a consequence, on entry to the second phase
the participants can diHer systematically from their initial state
despite a washout phase. For the same reason, cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both eHects are very likely in severe mental illness, we
would only have used data of the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, if relevant,
the additional treatment arms would have been presented in
comparisons. If data were binary, these would simply have been
added and combined within the two-by-two table. If data were
continuous, we would have combined data following the formula
in Section 7.7.3.8 (Combining groups) of the Cochrane Handbook
for Systemic Reviews of Interventions (Higgins 2011). Where the
additional treatment arms were not relevant, we would not have
reproduced these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss to follow-up, data must lose credibility (Xia
2009). We chose that, for any particular outcome, should more than
50% of data be unaccounted for, we would not reproduce these
data or use them within analyses. If, however, more than 50% of
those in one arm of a study were lost, but the total loss was less
than 50%, we would have addressed this within the 'Summary
of findings' tables by downgrading the certainty of the evidence.
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Finally, we also downgraded the certainty of the evidence within
the 'Summary of findings' tables should loss have been 25% to 50%
in total.
2. Binary
In the case where attrition for a binary outcome was between
0% and 50% and where these data were not clearly described,
we presented data on a 'once-randomised-always-analyse' basis
(an intention-to-treat (ITT) analysis). Those leaving the study early
were all assumed to have the same rates of negative outcome as
those who completed, with the exception of the outcome of death
and adverse eHects. For these outcomes, the rate of those who stay
in the study – in that particular arm of the trial – would have been
used for those who did not. We undertook a sensitivity analysis
testing how prone the primary outcomes were to change when
data only from people who completed the study to that point were
compared to the (ITT) analysis using the above assumptions.
3. Continuous
3.1. Attrition
We used data where attrition for a continuous outcome was
between 0% and 50%, and data only from people who complete the
study to that point were reported.
3.2. Standard deviations
If SDs were not reported, we would have tried to obtain the missing
values from the authors. If these were not available, where there
were missing measures of variance for continuous data, but an
exact standard error (SE) and CIs available for group means, and
either P value or t value available for diHerences in mean, we
could have calculated SDs according to the rules described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). When only the SE was reported, SDs were calculated by the
formula SD = SE × √(n). The Cochrane Handbook for Systematic
Reviews of Interventions presents detailed formulae for estimating
SDs from P, t or F values; CIs; ranges or other statistics (Higgins
2011). If these formulae did not apply, we would have calculated
the SDs according to a validated imputation method, which is
based on the SDs of the other included studies (Furukawa 2006).
Although some of these imputation strategies can introduce error,
the alternative would have been to exclude a given study's outcome
and thus to lose information. Nevertheless, we examined the
validity of the imputations in a sensitivity analysis that excluded
imputed values.
3.3. Assumptions about participants who leM trials early or were lost
to follow-up
Various methods are available to account for participants who
leO the trials early or were lost to follow-up. Some trials just
present the results of study completers; others use the method
of last observation carried forward (LOCF); while more recently,
methods such as multiple imputation or mixed-eHects models for
repeated measurements (MMRM) have become more of a standard.
While the latter methods seem to be somewhat better than LOCF
(Leon 2006), we feel that the high percentage of participants
leaving the studies early and diHerences between groups in their
reasons for doing so is oOen the core problem in randomised
schizophrenia trials. Therefore, we did not exclude studies based on
the statistical approach used. However, by preference we used the
more sophisticated approaches, that is, we preferred to use MMRM
or multiple-imputation to LOCF, and we only presented completer
analyses if some type of ITT data were not available at all. Moreover,
we addressed this issue in the item 'Incomplete outcome data' of
the 'Risk of bias' tool.
Assessment of heterogeneity
1. Clinical heterogeneity
We considered all included studies initially, without seeing
comparison data, to judge clinical heterogeneity. We simply
inspected all studies for people or situations who were clearly
outliers or situations that we had not predicted would arise and,
where found, discussed such situations or participant groups.
2. Methodological heterogeneity
We considered all included studies initially, without seeing
comparison data, to judge methodological heterogeneity. We
simply inspected all studies for clearly outlying methods, which




We inspected graphs visually to investigate the possibility of
statistical heterogeneity.
3.2. Employing the I2 statistic
We investigated heterogeneity between studies by considering the
I2 statistic alongside the Chi2 P value. The I2 statistic provides an
estimate of the percentage of inconsistency thought to be due
to chance (Higgins 2003). The importance of the observed value
of I2 statistic depends on 1. magnitude and direction of eHects
and 2. strength of evidence for heterogeneity (e.g. P value from
Chi2   test, or a CI for the I2 statistic). An I2 statistic estimate of
about 50% or greater accompanied by a statistically significant
Chi2 statistic would be interpreted as evidence of substantial
levels of heterogeneity (Section 9.5.2; Higgins 2011). When we
found substantial levels of heterogeneity in the primary outcome,
we explored reasons for heterogeneity (Subgroup analysis and
investigation of heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. These are
described in Section 10.1 of the Cochrane Handbook for Systemic
Reviews of Interventions (Higgins 2011). We searched for protocols
of included randomised trials. If the protocol was available, we
compared outcomes in the protocol and in the published report. If
the protocol was not available, we compared outcomes listed in the
Methods section of the trial report with actually reported results.
2. Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook for
Systemic Reviews of Interventions (Higgins 2011). We are aware that
funnel plots may be useful in investigating reporting biases but are
of limited power to detect small-study eHects. We did not use funnel
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plots for outcomes where there were 10 or fewer studies, or where
all studies were of similar sizes. In other cases, where funnel plots
were possible, we sought statistical advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-eHect or random-eHects models. The random-eHects
method incorporates an assumption that the diHerent studies are
estimating diHerent, yet related, intervention eHects. This oOen
seems to be true to us and the random-eHects model takes into
account diHerences between studies even if there is no statistically
significant heterogeneity. However, there is a disadvantage to the
random-eHects model as it puts added weight onto small studies,
which oOen are the most biased ones. Depending on the direction
of eHect, these studies can either inflate or deflate the eHect size.
We chose the random-eHects model for all analyses. The reader is,
however, able to choose to inspect the data using the fixed-eHect
model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1. Primary outcomes
We did not conduct a subgroup analysis as we did not anticipate
suHicient power to carry it out.
1.2. Clinical state, stage or problem
We proposed to undertake this review and provide an overview
of the eHects of Avatar Therapy for people with schizophrenia in
general. In addition, we reported data on subgroups of people in
the same clinical state, stage and with similar problems.
2. Investigation of heterogeneity
We reported if inconsistency was high. First, we investigated
whether data had been entered correctly. Second, if data were
correct, we inspected the graph visually and removed outlying
studies successively to see if homogeneity was restored. For this
review, we decided that should this occur with data contributing
to the summary finding of no more than around 10% of the total
weighting, we presented data. If not, we would not pool these data
and would discuss any issues. We knew of no supporting research
for this 10% cut-oH but investigated use of prediction intervals as
an alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity were
obvious we would have simply stated hypotheses regarding these
for future reviews or versions of this review. We did not anticipate
undertaking analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in some way that implied randomisation. For the
primary outcomes, we included these studies and if there was no
substantive diHerence when the implied randomised studies were
added to those with better description of randomisation, then all
data employed from these studies.
2. Assumptions for lost binary data
Where assumptions had to be made regarding people lost to follow-
up (see Dealing with missing data), we would have compared the
findings of the primary outcomes when we used our assumption
compared with completer data only. If there was a substantial
diHerence, we would have reported results and discuss them, but
continued to employ our assumption.
Where assumptions had to be made regarding missing SD data (see
Dealing with missing data), we would have compared the findings
of primary outcomes when we used our assumption compared
with complete data only. We would have undertaken a sensitivity
analysis to test how prone results were to change when completer
data only were compared to the imputed data using the above
assumption. If there was a substantial diHerence, we would have
reported results and discussed them, but continued to employ our
assumption.
3. Risk of bias
We analysed the eHects of excluding trials that were judged at high
risk of bias across one or more of the domains of randomisation
(implied as randomised with no further details available),
allocation concealment, blinding and outcome reporting for the
meta-analysis of the primary outcome (see Assessment of risk of
bias in included studies). If the exclusion of trials at high risk of bias
did not substantially alter the direction of eHect or the precision of
the eHect estimates, then data from these trials were included in
the analysis (Figure 2).
4. Imputed values
We undertook a sensitivity analysis to assess the eHects of including
data from trials where we used imputed values for ICC in calculating
the design eHect in cluster-randomised trials.
If there were substantial diHerences in the direction or precision of
eHect estimates in any of the sensitivity analyses, we did not pool
data from the excluded trials with the other trials contributing to
the outcome, but presented them separately.
5. Fixed and random e/ects
We synthesised data using a fixed-eHect model; however, we also
synthesised data for the primary outcomes using random-eHect
model to evaluate whether this altered the significance of the
results.
R E S U L T S
Description of studies
The search identified three studies as eligible for inclusion in
this review (ISRCTN65314790; LeH 2013; NCT03148639), and one
ongoing study (NCT03585127). For more details, see Characteristics
of included studies, Characteristics of excluded studies, and
Characteristics of ongoing studies tables.
Results of the search
The search strategy was run on the February 2013, December
2016 and 9 November 2018, which found 14 possibly relevant
references. We retrieved all of these for detailed evaluation.
Following inspection of the abstracts and, when necessary, full
papers, the 14 reports referred to four diHerent studies. We did
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not exclude any study because all four of them met our inclusion
criteria. However, one study was identified as an ongoing study
(NCT03585127). See also Figure 1.
Included studies
The three included trials randomised 195 participants. We
extracted data from the full-text publication of these trials, which
were published on 21 February 2013 (LeH 2013), 23 November
2017 (ISRCTN65314790), and 18 February 2018 (NCT03148639).
The characteristics of this trial are also summarised in the
Characteristics of included studies table.
1. Design and duration
All studies were stated to be randomised. Study duration across
the three included trials was identical; short-term and for seven
weeks. Study design varied: two were partial crossover (LeH 2013;
NCT03148639), and one was cross-sectional (ISRCTN65314790).
Blinding for two of the trials was single blind (ISRCTN65314790; LeH
2013), and one had no blinding (NCT03148639). Researchers in the
UK carried out two of the trials (ISRCTN65314790; LeH 2013), and
one took place in Canada (NCT03148639).
2. Participants
All participants were randomly assigned to the treatment groups.
In the ISRCTN65314790 study, participants had a primary diagnosis
of schizophrenia spectrum (International Classification of Diseases
10th Edition – Schizophrenia, schizotypal, delusional, and other
non-mood psychotic disorders; ICD10 F20–29) or aHective disorder
(F30–39) with psychotic symptoms, paranoid schizophrenia,
schizoaHective disorder, bipolar disorder, unspecified non-
organic psychosis, schizophrenia unspecified and depression
with psychotic symptoms. These people also had a history of
enduring auditory verbal hallucinations during previous 12 months
despite continued treatment. The participants in LeH 2013 had
been diagnosed by hearing persecutory voices for at least six
months, which had not responded adequately to antipsychotic
medication with history of hearing voices for more than one year.
In NCT03148639 participants were diagnosed with schizophrenia
or schizoaHective disorder with history of treatment-resistant
schizophrenia.
The range of age of participants was 14 to 75 years with parental
consent obtained for those under 18 years. All studies included
males and females and with two studies clearly reporting male to
female ratio (ISRCTN65314790; LeH 2013).
3. Size
The number of participants included in each study ranged between
19 and 150 but only one study included over 100 participants
(ISRCTN65314790).
4. Setting
LeH 2013 stated that they were focused on inpatients in hospital at
community mental health teams in Camden and Islington Mental
Health Trust, UK. ISRCTN65314790 took place in south London
and Maudsley NHS Trust, UK at sites remote from the clinic, while
NCT03148639 took place in the Institut Universitaire en Santé
Mentale de Montréal, Canada, and in the community.
5. Interventions
5.1. Avatar Therapy
ISRCTN65314790 reported that during the Avatar Therapy,
participants created a computerised representation of the entity
that they believed was the source of their main voice and then the
team set up the avatar in an introductory session, which included
a comprehensive assessment of the voice(s) and included verbatim
content. About 10 to 15 minutes of each session involved face-to-
face work with the avatar, wherein the therapist facilitated a direct
dialogue between the participant and the avatar. Participants sat in
one room facing their avatar on a computer monitor. The therapist
sat in a second room with a control panel that allowed them to
speak in his or her own voice, or as the avatar.
LeH 2013 and ISRCTN65314790 reported that the participants
created a representation of the entity they imagines as the source
of their avatar using computerised face animation soOware and in
the third study (NCT03148639), they reported that the participants
created an avatar best resembling the most distressing person or
entity believed to be the source of the malevolent voice, which
was designed to closely have both the face and the voice of the
'persecutor'. Over the course of the Avatar Therapy, the avatar's
interaction with the participant became gradually less abusive and
more supportive.
5.2. Treatment as usual/supportive counselling
Two trials compared Avatar Therapy with treatment as usual
(LeH 2013; NCT03148639). In LeH 2013, treatment as usual was
the patient's ongoing antipsychotic medication prescribed and
supervised by their referring psychiatrist, and in NCT03148639,
they oHered antipsychotic treatment and usual meetings with their
treating clinicians. ISRCTN65314790 used supportive counselling
as a control group. In this study, the intervention comprised
a manual-based, face-to-face supportive counselling approach
adapted with permission from that employed by the SoCRATES
(Acute Stroke or Transient Ischemic Attack Treated With Aspirin or
Ticagrelor and Patient Outcomes) Trial Group delivered by graduate
assistant psychologists who were recruited based on extensive
experience of working therapeutically in a psychosis context.
6. Outcomes
6.1. General
The trials reported mental state, insight, global state, leaving the
study early, adverse events and quality of life. None of the included
studies reported death, relapse or direct economic evaluation of
Avatar Therapy. Most reported outcomes were continuous and
many were skewed.
6.2. Outcome scales used in included studies
6.2.1. Mental state
• Calgary Depression Scale –CDS (Addington 1993)
The CDS is a nine-question scale with a 4-point rating (0 to 3), with
a score of zero indicating the absence of depression and a score of
3 indicating severe depression.
• Depression, Anxiety and Stress Scale –21 Items (DASS-21)
(Henry 2005)
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DASS-21 is a set of three self-report scales designed to measure the
emotional states of depression, anxiety and stress. Each of the three
DASS-21 scales contains seven items, divided into subscales with
similar content.
• Scale for the Assessment of Positive Symptoms (SAPS)
(Andreasen 1984)
SAPS is a 34-item scale where each item is being rated between 0
and 5 by clinicians to measure positive symptoms in schizophrenia
across four positive symptom domains: delusions, positive formal
thought disorder or disconnected thinking, bizarre behaviour and
hallucinations. The higher score is an indicator of more severe
positive symptoms.
• Positive and Negative Syndrome Scale (PANSS) (Kay 1986)
PANSS consists of 30 items and is rated using a seven-point
severity scale from absent to severe. It measures positive
symptoms, negative symptoms and an overall total score of general
psychopathology. A higher score indicates more severe symptoms.
Mean total score from this scale were reported by five studies,
three studies collected separate data for both positive and negative
symptoms (Ahmed 2015; Bryce 2018; Holzer 2014).
• Psychotic Symptom Rating Scales (PSYRATS) (Haddock 1999)
PSYRATS are semi-structured interviews designed to assess the
subjective characteristics of hallucinations and delusions. This is
used to capture the severity of several dimensions of auditory
hallucinations and delusions across two subclass, an auditory
hallucination subscale and a delusions subscale. The auditory
hallucination subscale includes 11 items while the delusional
subscale includes six items, with both subscales using a 5-
point ordinal scale to rate symptoms. Scores for the auditory
hallucination subscale can range from 0 to 44 and for the delusional
subscale can range from 0 to 24, with higher scores indicating more
severe symptoms. All items are scored 0 to 4, according to general
criteria: 0 = no problem, 1 = minimal or occasional, 2 = minor to
moderate, 3 = major and 4 = maximum severity.
• Scale for the Assessment of Negative Symptoms (SANS)
(Andreasen 1989)
SANS was the first instrument developed to provide comprehensive
assessment of negative symptoms in schizophrenia. It consists
of five scales that evaluate five diHerent aspects of negative
symptoms: alogia, aHective blunting, avolition-apathy, anhedonia-
asociality and attentional impairment. Each of these negative
symptoms can be rated globally, but, in addition, detailed
observations are made in order to achieve the global rating. It is
complemented by SAPS, which permits detailed evaluation and
global ratings of hallucinations, delusions, positive formal thought
disorder and bizarre behaviour. Together, the two scales provide a
comprehensive set of rating scales that measure the symptoms of
schizophrenia and to assess their change over time.
• Perceived Stress Reactivity Scale (PSRS) (Scholtz 2011)
PSRS is a 23-item questionnaire with five subscales and one
overall scale, based on an existing German-language instrument.
Perceived stress reactivity and related constructs were assessed
in 2040 participants from the UK, the US and Germany. The five-
factor structure of the PSRS was found to be similar in the three
countries. In the US sample, the questionnaire was applied using
two modes of administration (paper-pencil and computerised),
and measures were repeated aOer four weeks. Measurement
invariance analyses demonstrated full invariance across mode of
administration and partial invariance across gender and countries.
Scale scores diHered between countries and genders, with women
scoring higher on most scales.
6.2.2. Mental state: insight
• Revised Beliefs about Voices Questionnaire (BAVQ-R)
(Chadwick 2000)
The BAVQ-R was designed to assess these constructs, together
with two styles of responding (engagement and resistance). The
BAVQ-R is widely used in clinical and research settings, yet it
has not received validation of its constructs and factor structure.
This is used to measure the beliefs people hold about auditory
hallucinations, and both their emotional and behavioural reaction
to them. The scale has 35-items across five subscales. The subscales
relating to beliefs are a six-item malevolence subscale, a six-
item benevolence subscale and a six-item omnipotence subscale.
The two subscales relating to emotion and behavioural reactions
are a five-item resistance subscale and a four-item engagement
subscale. All responses are rated on a 4-point scale from 0 to 3 and
the high score means extremely distressed.
6.2.3. Quality of life
• Manchester Short Assessment of Quality of Life (MANSA)
(Priebe 1999)
The MANSA consists of three sections:
• personal details that are supposed to be consistent over time
(date of birth, gender, ethnic origin, and diagnosis);
• personal details that may potentially vary over time and
have to be re-documented if change has occurred (education;
employment status including type of occupation and
working hours per week; monthly income; state benefits;
living situation including number of children, people the
patient lives with, and type of residence);
• only 16 questions are to be asked every time the instrument
is applied. Four of these questions are termed objective and
to be answered with yes or no. Twelve questions are strictly
subjective.
The subjective questions obtain satisfaction with life as a
whole, job (or sheltered employment, or training/education,
or unemployment/retirement), financial situation, number and
quality of friendships, leisure activities, accommodation, personal
safety, people whose the patient lives with (or living alone), sex life,
relationship with family, physical health and mental health. Like in
the Lancashire Quality of Life Profile, satisfaction is rated on 7-point
rating scales (1 = negative extreme, 7 = positive extreme).
• Rosenberg Self-Esteem Scale (RSES) (Rosenberg 1965)
The RSES is widely used in social-science research. It uses a scale of
0 to 40 where a score less than 15 may indicate a problematic low
self-esteem.
The RSES is designed similar to the social-survey questionnaires.
It is a 10-item Likert-type scale with items answered on a 4-
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point scale – from strongly agree to strongly disagree. Five of the
items have positively worded statements and five have negatively
worded statements. The scale measures state self-esteem by asking
the respondents to reflect on their current feelings. RRSES is
considered a reliable and valid quantitative tool for self-esteem
assessment.
Implicit measures of self-esteem began to be used in the 1980s.
These rely on indirect measures of cognitive processing thought to
be linked to implicit self-esteem, including the Name Letter Task.
Such indirect measures are designed to reduce awareness of the
process of assessment. When used to assess implicit self-esteem,
psychologists feature self-relevant stimuli to the participant and
then measure how quickly a person identifies positive or negative
stimuli. For example, if a woman were given the self-relevant stimuli
of female and mother, psychologists would measure how quickly
she identified the negative word, evil, or the positive word, kind.
• Quality of Life Enjoyment and Satisfaction Questionnaire –
Short Form (QLESQ-SF) (Endicott 1993)
The QLESQ-SF evaluates general activities that are assessed in
the longer form of the QLESQ. Each item uses a 5-point scale
ranging from 1 (very poor) to 5 (very good). A total score is
derived from 14 items with a maximum score of 70 and with
higher scores indicating greater life satisfaction and enjoyment.
Participants rate their satisfaction with the following domains of
activity: physical health, feelings, work, household duties, school/
course work, leisure time activities and social relations. Test–retest
reliability for the QLESQ-SF has been shown to be.86 (Rapaport
2005) and internal consistency (Cronbach's alpha) has been shown
to range from 0.86 to 0.90 (Rapaport 2005; Wyrwich 2009).
7. Missing outcomes
Data were reported on the majority of primary outcomes. However,
none of the trials addressed economic outcomes. All three studies
reported their data as mean endpoint rather than change.
Several outcomes were in eHect missing because of problematic
reporting. ISRCTN65314790 did not separate data for each group
for the Reactions to Research Participation Questionnaire (RRPQ)
rendering data useless. NCT03148639 reported anxiety and fear
data only within a simple graph from which numbers could not be
extracted.
Finally, all the three studies reported skewed data which are
diHicult to analyses within systematic reviews.
8. Funding
One study was funded by the National Institute of Health
Research (NIHR; RC-PG-0308-10232) and Camden & Islington
NHS Foundation Trust (LeH 2013), and one of authors is part
funded by the NIHR Biomedical Research Centre at South London
and Maudsley NHS Foundation Trust and King's College London
(ISRCTN65314790). Two of the authors in NCT03148639 are holders
of a grant from Otsuka Pharmaceuticals.
9. Conflicts of Interest
Two of the authors of ISRCTN65314790 declared patents pending
on the avatar system and in LeH 2013 there also could be conflicts of
interest given that the authors involved in the study were the same
team that designed Avatar Therapy.
Excluded studies
There were no excluded studies.
Studies awaiting classification
There are no studies awaiting classification.
Ongoing studies
There is currently one ongoing study in this review (NCT03585127).
This small study comparing Avatar Therapy with a more cognitive
behavioural approach should be complete (due to finish December
2019) and we will include the results in the review update.
Risk of bias in included studies
Overall risk of bias in individual studies are also illustrated in Figure
2; Figure 3; and Characteristics of included studies table.
Allocation
We assessed two studies at low risk for random sequence
generation. LeH 2013 randomised using a computer-generated
series with 12 blocks by an independent statistician and in
ISRCTN65314790, the participants were randomly assigned (1:1) to
receive Avatar Therapy or supportive counselling with randomised
permuted blocks. NCT03148639 was at high risk as they described
participants randomly allocated (1:1 ratio) to either Avatar Therapy
or treatment as usual but this ratio does not fit with the actual
number of participants in the two groups.
For allocation concealment, ISRCTN65314790 was at low risk as
an independent web-based service was provided to maintain
allocation concealment. LeH 2013 was at unclear risk as, although
participants were randomised into one of two groups by an
independent statistician using a computer-generated series with
blocks of 12. It is not clear, however, if all of the team were
informed of the allocated group or care co-ordinators/case
managers, blinded to other allocation decisions, informed the
study's participants. We assessed NCT03148639 at unclear risk as
they did not provide any clear and detailed information about
allocation concealment.
Blinding
We ranked ISRCTN65314790 at unclear risk for both performance
and detection bias as the study was blind only for assessors. LeH
2013 had an unclear risk of performance and detection bias as it was
not clear whether there was any blinding. NCT03148639 was also at
unclear risk as they did not report any information on blinding.
Incomplete outcome data
For incomplete outcome reporting we had to rank ISRCTN65314790
at high risk, as there were no clear data about the adverse events
and unusable information about satisfaction (RRPQ). We ranked
LeH 2013 at high risk, as there was attrition from the intervention
group; however, no further analysis was undertaken to account
for these missing data. Also there was diHerence between protocol
and full publication of the trial about the duration of the trials –
changing from 11 months to six weeks. We ranked NCT03148639 at
high risk, as they reported postcross-over data – amalgamating the
Avatar Therapy plus treatment as usual rather than the outcomes
for Avatar Therapy and treatment as usual separately. We contacted
the authors via email for more information. They supplied data on
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loss to follow-up, rehospitalisation and the mean outcome data for
Avatar Therapy group before crossover.
Selective reporting
None of the studies were free from selective reporting.
ISRCTN65314790 was at unclear risk, as they frequently used
"significantly greater improvement" but did not describe how this
was measured, they also reported confusing information in their
CONSORT flow diagram. LeH 2013 was at high risk for reporting
bias as some of the important outcomes such as adverse events
were not clearly reported and a protocol was not published prior to
the study results being reported. NCT03148639 was at high risk, as
there was no clear information in order to allocation concealment
and blinding, adverse events and number of participants.
Other potential sources of bias
None of the studies were free from other biases. We had concerns
with ISRCTN65314790, as two of authors declared patents pending
on the avatar system used in the study. We also assessed LeH 2013
at high risk of other bias, as the study was funded by the NIHR and
Bridging Funding from Camden & Islington NHS Foundation Trust
but the authors involved in the study were the same team that had
designed Avatar Therapy. In addition, information in the published
trial was diHerent to the submitted abstract. NCT03148639 was at
unclear risk as two of the study authors were holders of a grant from
Otsuka Pharmaceuticals.
E9ects of interventions
See: Summary of findings 1 Avatar Therapy compared to
treatment as usual (all short-term) for schizophrenia or related
disorders; Summary of findings 2 Avatar Therapy compared to
supportive counselling (all short-term) for schizophrenia or related
disorders
We identified three randomised trials from which it was possible
to extract numerical data. We categorised studies into two
comparisons: Avatar Therapy versus treatment as usual and Avatar
Therapy versus supportive counselling.
1. Comparison 1: Avatar Therapy versus treatment as usual
1.1. Mental state: 1a. Specific – positive – average endpoint
score (PANSS-P, high = poor) – short term
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (MD –1.93, 95% CI –5.10 to 1.24;
studies = 1; participants = 19; very-low certainty evidence; Analysis
1.1).
1.2. Mental state: 1b. Specific – insight – average endpoint score
(BAVQ-R attitude to voices, high = poor) – short term
Analysis of insight data showed participants in the Avatar Therapy
group had clearly higher average BAVQ-R endpoint scores (MD –
5.97, 95% CI –10.98 to –0.96; studies = 1; participants = 19; very-low
certainty evidence; Analysis 1.2).
1.3. Mental state: 1c. Specific – insight – average endpoint
attitude to voice score (BAVQ-R attitude to voices, high = poor,
skewed data) – short term
Data reported for this outcome were skewed and we have
presented them as 'other data' (Analysis 1.3).
1.4. Mental state: 1d. Specific – depression – average endpoint
score (various scales, high = poor, skewed data) – short term
Data reported for this outcome were skewed and we have
presented them as 'other data' (Analysis 1.4).
1.5. Mental state: 1e. Specific – negative – average endpoint
score (PANSS-N, high = poor) – short term
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (MD –1.17, 95% CI –5.70 to 3.36;
studies = 1; participants = 19; Analysis 1.5).
1.6. Mental state: 2a. General – total – average endpoint score
(PANSS total, high = poor) – short term
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (MD –8.07, 95% CI –19.49 to 3.35;
studies = 1; participants = 19; Analysis 1.6).
1.7. Mental state: 2b. General – total – average endpoint score
(PSYRATS total, high = poor) – short term
Analysis of general mental state data showed participants in the
Avatar Therapy group had clearly lower average PSYRATS endpoint
scores(MD –5.51, 95% CI –9.15 to –1.87; studies = 1; participants =
19; very-low certainty evidence; Analysis 1.7).
1.8. Mental state: 2c. General – total – average endpoint score
(PSRS, high = poor, skewed data) – short term
Data reported for this outcome were skewed and we have
presented them as 'other data' (Analysis 1.8).
1.9. Global state: 1. Any change – needing counselling and
support – short term
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 1.85, 95% CI 0.09 to 40.05;
studies = 1; participants = 19; Analysis 1.9).
1.10. Global state: 2. Rehospitalised – short term
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RD 0.00, 95% CI –0.20 to 0.20;
studies = 1; participants = 19; low-certainty evidence; Analysis 1.10).
1.11. Leaving study early: 1. For any reason – short term
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 11.27, 95% CI 0.70 to 181.41;
studies = 1; participants = 26; low-certainty evidence; Analysis 1.11).
1.12. Leaving study early: 2. For specific reason – short term
One trial reported specific reasons for attrition (Analysis 1.12).
1.12.1. Change in medication
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 2.60, 95% CI 0.12 to 58.48;
studies = 1; participants = 26).
1.12.2. Fear of voice
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 9.53, 95% CI 0.58 to 156.49;
studies = 1; participants = 26).
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1.13. Adverse events: anxiety – short term
One trial reported incidence of anxiety (Analysis 1.13).
1.13.1. AMer first session
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 5.54, 95% CI 0.34 to 89.80;
studies = 1; participants = 19; low-certainty evidence).
1.13.2. Self-reported
No participants reported self-reported incidence of anxiety.
1.14. Quality of life: average endpoint score (QLESQ-SF, high =
good) – short term
Analyses of reported quality of life data showed participants in
the Avatar Therapy group had clearly higher average QLWSQ-
SF endpoint scores (MD 9.99, 95% CI 3.89 to 16.09; studies = 1;
participants = 19; very low-certainty evidence; Analysis 1.14).
2. Comparison 2: Avatar Therapy versus supportive
counselling
2.1. Mental state: 1a. Specific – positive – average endpoint
score (SAPS, high = good, skewed data)
Data reported for this outcome were skewed and we have
presented them as 'other data' (Analysis 2.1).
2.2. Mental state: 1b. Specific – insight – average endpoint score
(various scales, high = poor) – short term
Various measures of insight were reported, using various scales
(Analysis 2.2).
2.2.1. Attitude to voices (BAVQ-R)
Analysis of insight data showed participants in the Avatar Therapy
group had clearly lower average BAVQ-R 'attitude to voice' endpoint
scores (MD –8.39, 95% CI –14.31 to –2.47; studies = 1; participants =
124; low-certainty evidence).
2.2.2. Acceptance of voice (Voices Acceptance and Action Scale; VAAS)
Analysis of insight data showed participants in the Avatar Therapy
group had clearly higher average VAAS 'acceptance of voice'
endpoint scores (MD 4.73, 95% CI 1.40 to 8.06; studies = 1;
participants = 124).
2.2.3. Power of voice (Voice Power Di9erential Scale; VPDS)
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (MD –0.36, 95% CI –0.89 to 0.17;
studies = 1; participants = 115).
2.2.4. Total (VAAS)
Analysis of insight data showed participants in the Avatar Therapy
group had clearly lower average VAAS total endpoint scores (MD –
2.91, 95% CI –5.71 to –0.11; studies = 1; participants = 115).
2.3. Mental state: 1c. Specific – depression and anxiety – average
endpoint score (high = poor, skewed data) – short term
Data reported for this outcome were skewed and we have
presented them as 'other data' (Analysis 2.3).
2.4. Mental state: 1d. Specific – negative – average endpoint
score (SANS, high = good, skewed data) – short term
Data reported for this outcome were skewed and we have
presented them as 'other data' (Analysis 2.4).
2.5. Mental state: 2a. General – total – average endpoint score
(PSYRATS, high score = poor) – short term
Analysis of reported general mental state data showed participants
in the Avatar Therapy group had clearly lower average PSYRATS
endpoint scores (MD –4.74, 95% CI –8.01 to –1.47; studies = 1;
participants = 124; low-certainty evidence; Analysis 2.5).
2.6. Leaving study early: 1a. For any reason
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 1.06, 95% CI 0.59 to
1.89; studies = 1; participants = 150; moderate-certainty evidence;
Analysis 2.6).
2.7. Leaving study early: 1b. For specific reason – short term
One trial reported specific reasons for leaving the study early
(Analysis 2.7).
2.7.1. Not contactable
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 3.00, 95% CI 0.63 to 14.39;
studies = 1; participants = 150).
2.7.2. Refused
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 0.83, 95% CI 0.38 to 1.81;
studies = 1; participants = 150).
2.7.3. Unwell
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 0.67, 95% CI 0.11 to 3.88;
studies = 1; participants = 150).
2.7.4. Attended no sessions
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 0.33, 95% CI 0.13 to 0.87;
studies = 1; participants = 150).
2.7.5. Discontinued – session 1to 6
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (RR 1.70, 95% CI 0.83 to 3.47;
studies = 1; participants = 150).
2.8. Quality of life: average endpoint score (various scales, high
= good) – short term
Quality of life data were reported using various scales (Analysis 2.8).
2.8.1. MANSA
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (MD 2.69, 95% CI –1.48 to 6.86;
studies = 1; participants = 120; low-certainty evidence).
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2.8.2. Rosenberg Self-Esteem Scale
Analysis of reported data showed no clear diHerence between
treatment groups for this outcome (MD 0.55, 95% CI –1.55 to 2.65;
studies = 1; participants = 121).
D I S C U S S I O N
Summary of main results
1. Avatar Therapy compared to treatment as usual (all short-
term) for schizophrenia or related disorders
Two trials compared Avatar Therapy to treatment as usual (LeH
2013; NCT03148639).
1.1. Mental state
It is possible that we, in our protocol, set the expectations too
high for measures of mental state. We had hoped to find some
binary outcomes such as 'improved to an important extent' and the
small trial (participants = 19) only reported continuous measures.
It is understandable that a pilot study takes fine-grain measures
as outcomes to see if there is a suggestion on a shiO on these,
hopefully sensitive, measures. There was, however, no suggestion,
even on these measures and we found no data for binary outcomes.
The study did not make data available so that binary analyses could
be undertaken, even if this would have been grossly underpowered.
We would like more data sets to be made available so that
combination of findings could be achieved in the future as new
trials emerge. Currently our certainty about any mental state
evidence is very low – but there are very few data to have any degree
of certainty over.
1.2. Global state
The same applied to global state measures. There were very
few data from one small short-term trial (participants = 19).
However, relapse was reported – albeit in the negative. This 'more
concrete' outcome is useful when it is impossible to blind outcome
measuring.
1.3. Leaving the study early
Six of 14 people leO the Avatar Therapy group, and none leO the trial
from the treatment as usual group – out of 12 people assigned to
that group. This could be a function of the trial design – allowing
exiting from the avatar group with more ease than the treatment as
usual group – and probably this is the explanation. However, there
is a worry that this could indicate that the Avatar Therapy approach
was, somehow, unacceptable to people with schizophrenia. The
evidence is of low certainty (Analysis 1.11), but this is one finding
that should be closely monitored in future studies.
1.4. Adverse e/ects: at least one important adverse e/ect
1.4.1. Anxiety – aMer first session
There was no clear diHerence between Avatar Therapy and
treatment as usual for number of participants with anxiety aOer
their first session of treatment but we have low certainty for this
finding (Analysis 1.13), and it does seem to concur with the 'leaving
the study early' finding reported and discussed above. The therapy
could increase anxiety. This, in itself, may not be problematic and
could have a positive eHect, but this is speculation at this point. We
have less evidence of a positive eHect than we have of a suggestion
of the Avatar Therapy being unacceptable and causing anxiety.
1.5. Quality of life: any change in quality of life
1.5.1. Average endpoint score (QLESQ-SF, high score = good)
Average scores were not what we prestated in our protocol as a
preferred outcome. We had high levels of uncertainty about any
finding related to quality of life but the one small trial that reported
on this found a possible small positive eHect for Avatar Therapy
(participants = 19; Analysis 1.14). This could be a random finding –
a spurious or rogue result. It is impossible to know. Should it be a
real eHect, it will be possible to replicate in future, larger trials.
1.6. Functioning
Simple recording of functioning, on day-to-day tasks, is not diHicult
to add to trial design. We look forward to this being included in
future studies.
2. Avatar Therapy compared to supportive counselling (all
short-term) for schizophrenia or related disorders
One trial compared Avatar Therapy to supportive counselling
(ISRCTN65314790).
2.1. Mental state
The trial (participants = 124) did not report binary data – or data in
a way that could be made into binary. The nearest proxy measure
for a general mental state outcome did, however, show benefit for
those allocated to Avatar Therapy (low-certainty evidence; Analysis
2.5). It could be that the supportive counselling was detrimental
and that the Avatar Therapy approach better only in contrast to
this. However, if this is a real eHect, this should be replicated, and,
explained. We remain unclear what an average drop of around
5 points on the PSYRATS score would mean for a person with
schizophrenia.
When it came to a more specific measure (insight) the finding was
not dissimilar (low-certainty evidence; Analysis 2.2). Again, it does
seem positive that there is a drop of around 8 points on the BAVQ-
R – but we are unclear if this would really make any noticeable
diHerence clinically.
2.2. Global state
The trial did not report this relatively simple outcome. This is a
missed opportunity as such a finding would be of interest and of
value to future updates as more data become available.
2.3. Leaving the study early
The study had a small proportion of participants leaving early
(about 20%), over a long period of time, which was balanced
between groups (moderate-certainty evidence; Analysis 2.6).
2.4. Adverse e/ects: at least one important adverse e/ect
The trial did not address adverse eHects, which is concerning as,
at the very least, studies should report them. It is known that
supportive therapy can have adverse consequences (Buckley 2015),
so not having a clear mechanism for recording these would not
seem to be the best design of trial. A drug trial not attempting
to record adverse eHects would not be allowed to proceed. It is a
diHicult argument that the therapy trials should have diHerent and
lesser standards.
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2.5. Quality of life: any change in quality of life
We found very low-certainty evidence for quality of life (Analysis
2.8) – and there was no clear diHerence between groups. These are
important outcomes that should be replicated in future trials.
2.6. Functioning
The trial did not address functioning, which greatly devalued this
potentially important trial.
Overall completeness and applicability of evidence
1. Completeness
This systematic review included three studies (participants = 195).
Two studies compared Avatar Therapy with treatment as usual (LeH
2013; NCT03148639), and one study compared Avatar Therapy with
supportive counselling (ISRCTN65314790). Pooling of data from
these studies was not possible. All three studies reported short-
term outcomes (seven sessions in seven weeks). Therefore, we
have no information about the medium- or long-term eHects of the
interventions used in these trials and the numerical data we do
have are uncertain.
None of the studies reported information related to general
functioning, cognitive functioning and economic outcomes (direct,
indirect and cost eHective). The data that are reported are not fully
consistent across the small studies making synthesis problematic.
Much of the data reported were skewed. This is not a criticism
of these data as it is likely that many of the so-called continuous
measures do produce data with considerable skew. The criticism
is that these data are not publicly available. Reporting was
incomplete.
2. Applicability
The three studies had a wide group of participants and included
both men and women between 14 to 75 years old. All studies,
however, were conducted in high-income countries, and centres of
excellence so, currently, would be diHicult to apply outside of that
environment. Much more widespread, generalisable, real-world
work would have to be done to support wide applicability.
Quality of the evidence
In these decades aOer CONSORT (www.consort-statement.org), no
trial should be unclear in how randomisation was undertaken and
then concealed. The three included studies were threatened by
risks of inclusion of bias at this most fundamental of stages. With
thoughtful design and good conduct and reporting, all future Avatar
Therapy studies could have risk of bias minimised. However, at
present, the certainty of the evidence is not good and all results
have to be treated with considerable caution.
Potential biases in the review process
To avoid introducing our own bias to this review we strictly followed
Cochrane methods for conducting reviews and have reported all
available processes, methods and data transparently so that they
can be checked if needed. We would welcome any comments or
additional data to improve this review.
Agreements and disagreements with other studies or
reviews
To the best of our knowledge, this is the only systematic review of
Avatar Therapy.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Currently, there is no clear evidence for – or against – using Avatar
Therapy as a treatment for people with serious mental illness.
The intervention is still an experimental treatment. People with
schizophrenia could help generate much more evidence by taking
part in good evaluative studies but also make this contingent on all
data from their trials being made publicly available.
2. For clinicians
This review is unable, at the moment, to provide adequate evidence
to inform clinicians about the value of Avatar Therapy for people
with schizophrenia. If this therapy is being considered, the person
with schizophrenia should be informed of the experimental nature
of the treatment and the details should be explained to them in a
transparent way so that they could make an informed decision.
3. For policy makers
Currently, there is no clear evidence for encouraging Avatar Therapy
as a treatment for people with schizophrenia. Furthermore, there
are no data in terms of economic outcomes for using Avatar Therapy
in a clinical setting. We believe that more high-quality and long-
term studies should be undertaken in this area to explore the
eHects, safety and costs of this novel intervention.
Implications for research
1. General
Given that there is insuHicient research to determine if Avatar
Therapy is eHective, there is a need for further research to establish
its value – or lack of it – in this population. In this fast-moving area,
it is likely that additional studies are being planned. All of them
should report the standards required by CONSORT (www.consort-
statement.org). In addition, the need for studies completed by
teams without a 'stake' in Avatar Therapy is absolutely necessary,




We know that the design of trials of any treatment is a painstaking
process that takes time and great eHort. However, we also
have given this topic some thought and suggested an outline
design (Table 1). We recognise that there is one ongoing study
(NCT03585127), but this, too, is small (participants = 50) and is
unlikely to definitively answer clinically meaningful questions. The
current available data were extracted from three small short-term
studies with fairly high risks of bias. Due to the nature of Avatar
Therapy, blinding participants is problematic but the use of suitable
outcomes could partly compensate for this. There is a real diHiculty
that researchers with enthusiasm for a therapy are the ones to
undertake the trials on their own invention – and are likely to
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continue to be. Every eHort should be made – and be seen to be
made – to ensure distance of the pioneering inventors of Avatar
Therapy from its evaluation without the loss of the necessary
expertise.
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Duration: over 7 sessions (1 introductory session + 6 therapy session) weekly 50 minutes each
Design: cross-sectional
Country: UK
Participants Diagnosis: primary diagnosis of schizophrenia spectrum (ICD10 F20–29) or affective disorder (F30–39
with psychotic symptoms
N = 150
Age: mean about 43 years, range 18–65 years
Sex: men and women
Setting: South London and Maudsley NHS Trust, sites remote from the clinic
History: enduring auditory verbal hallucinations during previous 12 months despite continued treat-
ment
Interventions 1. Avatar Therapy: participants created a computerised representation of the entity that they believed
was the source of their main voice and then the team set up the avatar in an introductory session,
which included a comprehensive assessment of the voice(s) and included verbatim content.
10–15 minutes of each session involved face-to-face work with the avatar, where in the therapist facil-
itated a direct dialogue between the participant and the avatar. Participants sat in 1 room facing their
avatar on a computer monitor. The therapist sat in a second room with a control panel that allowed
them to speak in his or her own voice, or as the avatar. N= 75.
2. Supportive counselling: a manual-based, face-to-face supportive counselling approach adapted with
permission from that employed by the SoCRATES Trial Group delivered by graduate assistant psycholo-
gists who were recruited on the basis of extensive experience of working therapeutically in a psychosis
context. N= 75.
Outcomes Mental state – general: PSYRATS total
Mental state – specific (insight): BAVQ-R total, VAAS acceptance, VPDS voice power, VPDS total
Mental state – specific (depression and anxiety): CDS, DASS-21 total, Psychotic Symptom Rating Mental
state – specific (negative symptoms): SANS
Leaving study early: any reason, specific reasons
Quality of life: MANSA, Rosenberg Self-Esteem Scale
Unable to use
Mental state – specific (positive): SAPS (skewed data)
Physiological measures – not protocol outcomes
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Participants were randomly assigned (1:1) to receive AVATAR therapy
or supportive counselling with randomised permuted blocks (block size ran-




Low risk Quote: "independent web-based service provided by the UKCRC [UK Clinical
Research Collaboration] Registered Clinical Trials Unit at King's College Lon-






Unclear risk Quote: "assessors"
Comment: unclear risk
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "All assessments were done by research assessors who were masked
to therapy allocation. To avoid unmasking, we ensured that assessors did not
have access to clinical records after the baseline (pre-randomisation) assess-
ment or access to the therapy database at any stage, that all assessments were
done at sites remote from the clinic, and that participants were reminded be-









Unclear risk All important outcomes have been reported but a few of the outcomes in reg-
istered protocol have not been reported in final report of the trials.
Comment: unclear
Other bias High risk Quote: "one of authors is part funded by the National Institute for Health Re-
search (NIHR) Biomedical Research Centre at South London and Maudsley
NHS Foundation Trust and King's College London. Two of the authors declared
patents pending on the avatar system. The funding source had no input in the
preparation of this manuscript".
Quote: "significantly greater improvement" used frequently and confusing in-








Duration: 11 months of treatment stated in protocol but in the final study it stated 6 sessions of 30 min-
utes + 1 week' follow-up, because there was just 1 therapist, which limited the sessionsa
Le9 2013 
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Design: partial cross-overb
Country: UK
Participants Diagnosis: hearing persecutory voices for ≥ 6 months, which had not responded adequately to antipsy-
chotic medication.
N= 26
Age: 14–75 years, no more informationc
Sex: male and female
Setting: hospital, community mental health teams in Camden and Islington Mental Health Trust, UK
History: 22 participants had complete medical compliance, 2 partial and 2 none. 15 had ≥ 10 years of
hearing voices, 3 had 6–10 years, and 8 had 1–5 years.
Inclusion criteria: experienced persecutory auditory hallucinations for ≥ 6 months and these hallucina-
tions had not responded adequately to antipsychotic medications.
Excluded: organic brain disease and substance misuse
Interventions 1. Avatar Therapy: participants created a representation of the entity they imagined as the source of
their auditory hallucinations using computerised face animation software. N= 14.
2. Treatment as usual (delayed therapy group): participant's ongoing antipsychotic medication pre-
scribed and supervised by their referring psychiatrist. N= 12.
Outcomes Mental state – specific (insight): BAVQ-R attitude to voice
Mental state – specific (depression and anxiety): CDS
Leaving the study early: for any reason, for specific reason
Unable to use:
Mental state – general: PSRS (skewed data)
Notes It is unclear how the participants were approached for recruitment. Participants were recruited from
the community mental health team; however it is unclear if all participants in the team were ap-
proached or care co-ordinators/case managers selectively informed participants who they thought
were appropriate to enter the study.
aThere was a difference between protocol and final study report about the duration of study which has
a change from 11 months to 6 weeks + 1 week' follow-up.
bThe immediate therapy group did not crossover into a no-therapy block as we expected the therapy to
have carry-over effects.
cParental consent was obtained for participants aged under 18 years.
The study was approved by the West Kent Research Ethics Committee.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "after baseline assessment, patients were randomised into one of two
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Allocation concealment
(selection bias)
Unclear risk Quote: "patients were randomised into one of two groups using a comput-
er-generated series with blocks of 12, generated by an independent statisti-
cian".
Comment: it was unclear if all participants in the team were approached or
care co-ordinators/case managers selectively informed participants who they






Unclear risk Quote: "both groups of patients were assessed at each time point by a user-re-
searcher who knew neither the group to which each patient was assigned, nor
the design of the trial."
Comment: participants were not blind to the intervention. The authors did not
describe this. We rated unclear only because it appeared that Avatar Therapy
could not be blinded; however, it may be possible to provide sham therapy.
Comment: unclear
Blinding of outcome as-
sessment (detection bias)
All outcomes






High risk Comment: no useful and clear information about attrition.
Comment: some participants leO early from the intervention group; however,
no further analysis was undertaken to account for their missing data.
Comment: there was a difference between protocol and article about the du-





High risk Comment: no useful information on adverse events and attrition.
Comment: some of the important outcomes such as adverse events were not
clearly reported. Furthermore, protocol was not published prior to the study
results being reported.
Comment: high risk
Other bias High risk Quote: "the study was funded by the National Institute of Health Research (RC-
PG-0308-10232) and Bridging Funding from Camden & Islington NHS Founda-
tion Trust. Possible conflict of interest given that the authors involved in the
study were the same team that designed avatar therapy."
Comment: the article information was different from the abstract.
Comment: very little information about the referral process, or demographic
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Methods Allocation: randomised
Blindness: none
Duration: 7-week phase IIa
Design: partial cross-over
Country: Canada
Participants Diagnoses: schizophrenia or schizoaffective disorder
N= 19
Age: mean about 43 years
Sex: male and femaleb
Setting: Institut Universitaire en Santé Mentale de Montréal, Canada; institute and in community
History: treatment-resistant schizophrenia, aged ≥ 18 years
Interventions 1. Avatar Therapy: participants created an avatar best resembling the most distressing person or enti-
ty believed to be the source of the malevolent voice, which was designed to closely have both the face
and the voice of the "persecutor". Over the course of therapy, the avatar's interaction with the par-
ticipant became gradually less abusive and more supportive. 1 avatar creation session + 6 weekly 45-
minute further sessions. N= 12.
2. Treatment as usual: antipsychotic treatment and usual meetings with their treating clinicians. N= 7.
Outcomes Mental state – general: PANSS, PSYRATS total
Mental state – specific (depression and anxiety): BDI
Mental state – specific (insight): BAVQ-R
Mental state – specific (positive): PANSS
Global state: rehospitalised
Adverse events: various
Quality of life: QLESQ-SF
Unable to use:
Mental state: self-reported anxiety, fear – unable to extract data from graph
Notes Wrote to authors 24 November 2018 and Dr Laura Dellazizzo on behalf of Dr Alexandre Dumais, kind-
ly replied supplying data on loss to follow-up, rehospitalisation and Avatar Therapy group before
crossover.
aThe total amount of weeks was 7 comprising of 1 avatar creation session and 6 therapeutic sessions.
bThere is no clear and detailed information about it from the baseline.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quote: "patients fulfilling inclusion criteria were randomly allocated (1:1 ratio)
to either VR-assisted therapy (VRT) or treatment-as-usual (TAU)".
NCT03148639  (Continued)
Avatar Therapy for people with schizophrenia or related disorders (Review)









Cochrane Database of Systematic Reviews
Comment: concern as the number of participants in 2 random groups are dif-
ferent which is not possible in 1:1 ratio.
Allocation concealment
(selection bias)






Unclear risk No information
Comment: unclear
Blinding of outcome as-
sessment (detection bias)
All outcomes





High risk Comment: there was no information in the article because they had reported
the crossover data (therapy +treatment as usual) as outcome report instead of
reporting therapy outcome report separately. We contacted them via email for
more information, and they kindly replied supplying data on loss to follow-up,
rehospitalisation and the mean outcome data for avatar therapy group before





High risk Comment: there was no clear information regarding adverse events and num-
ber of participants.
Comment: high risk
Other bias Unclear risk Quote: "two of authors are holder of a grant from Otsuka Pharmaceuticals."
Comment: unclear
NCT03148639  (Continued)
BAVQ-R: Revised Beliefs about Voices Questionnaire; BDI: Beck Depression Inventory; CDS: Calgary Depression Scale; CI: confidence
interval; DASS-21: Depression, Anxiety and Stress Scale – 21 Items; ICD10 F20–29: International Classification of Diseases 10th Edition
– Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders; MANSA: Manchester Short Assessment of Quality of
Life; MD: mean diHerence; N: number of participants; PANSS-P: Positive and Negative Syndrome Scale – Positive; PSYRATS: Psychotic
Symptom Rating Scale; QLESQ-SF: Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; RCT: randomised controlled trial;
RD: risk diHerence; RR: risk ratio; RRPQ: Reactions to Research Participation Questionnaire; SANS: Scale for the Assessment of Negative
Symptoms; SAPS: Scale for the Assessment of Positive Symptoms; SoCRATES: Acute Stroke or Transient Ischemic Attack Treated With
Aspirin or Ticagrelor and Patient Outcomes; VAAS: Voices Acceptance and Action Scale; VPDS: Voice Power DiHerential Scale.
 
Characteristics of ongoing studies [ordered by study ID]
 






Setting: Institut Universitaire en Santé Mentale de Montréal, Montréal, Quebec, Canada
NCT03585127 
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Participants Diagnosis: people with a auditory hallucination, verbal and treatment-resistant schizophrenia,
DSM-5 diagnosis of schizophrenia or schizoaffective disorder
History: participants randomised from waiting list and referred to research staH
N = 50
Age: > 18 years
Sex: men and women
Inclusion criteria: DSM-5 diagnosis of schizophrenia or schizoaffective disorder, aged ≥ 18 years
Exclusion criteria: any change in medication within the past 2 months, substance-use disorder
within last 12 months, neurological disorder or unstable and serious physical illness, ongoing psy-
chotic episode, cognitive behavioural therapy for psychosis within the last 12 months
Interventions 1. Avatar Therapy: programme for 9 individual and weekly sessions of 1 hour. N= 25
2. Cognitive behavioural therapy: programme for 9 individual and weekly sessions of 1 hour. N= 25
Outcomes Mental state (binary outcomes)
Change in Revised Beliefs About Voices Questionnaire
Change in Positive And Negative Syndrome
Change in Beck Depression Inventory – II
Change in Quality of Life Enjoyment and Satisfaction Questionnaire
Change in Empowerment scale (Making Decisions) – Revised Short Form
Change in Igroup Presence Questionnaire
No information:
Relapses (binary outcomes)
Quality of life (binary outcomes)
Costs: cost of services, cost of care
Adverse events related to yoga (number and type of injuries)
Service outcomes: days in hospital, time attending outpatient psychiatric clinic
Starting date 1 March 2017




DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition; N: number of participants.
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Comparison 1.   Avatar therapy versus treatment as usual





Statistical method Effect size
1.1 Mental state: 1a. Specific – positive – average end-
point score (PANSS-P, high = poor) – short term




1.2 Mental state: 1b. Specific – insight – average end-
point score (BAVQ-R attitude to voices, high = poor) –
short term
1   Mean Difference (IV, Fixed,
95% CI)
Subtotals only
1.3 Mental state: 1c. Specific – insight – average end-
point score (BAVQ-R attitude to voices, high = poor,
skewed data) – short term
1   Other data No numeric da-
ta
1.4 Mental state: 1d. Specific – depression – average
endpoint score (various scales, high = poor, skewed
data – short term
2   Other data No numeric da-
ta
1.4.1 BDI 1   Other data No numeric da-
ta
1.4.2 CDS 1   Other data No numeric da-
ta
1.5 Mental state: 1e. Specific – negative – average end-
point score (PANSS-N, high = poor) – short term
1   Mean Difference (IV, Fixed,
95% CI)
Subtotals only
1.6 Mental state: 2a. General – total – average end-
point score (PANSS total, high = poor) – short term)




1.7 Mental state: 2b. General – total – average end-
point score ( PSYRATS total, high = poor) – short term




1.8 Mental state: 2c. General – total – average end-
point score (PSRS, high poor, skewed data) – short
term
1   Other data No numeric da-
ta
1.9 Global state: 1. Any change – needing counselling
and support – short term




1.10 Global state: 2. Relapse (rehospitalised) – short
term




1.11 Leaving study early: 1. For any reason – short
term




1.12 Leaving study early: 2. For specific reason – short
term
1   Risk Ratio (M-H, Fixed, 95%
CI)
Subtotals only
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Statistical method Effect size
1.13 Adverse effects: anxiety – short term 1   Risk Ratio (M-H, Fixed, 95%
CI)
Subtotals only




1.13.2 Self-reported 1 19 Risk Ratio (M-H, Fixed, 95%
CI)
Not estimable
1.14 Quality of life: average endpoint score (QLESQ-
SF, high = good) – short term






Analysis 1.1.   Comparison 1: Avatar therapy versus treatment as usual, Outcome 1: Mental





Test for overall effect: Z = 1.19 (P = 0.23)





















IV, Fixed, 95% CI
-1.93 [-5.10 , 1.24]
-1.93 [-5.10 , 1.24]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours avatar therapy Favours treatment as usual
 
 
Analysis 1.2.   Comparison 1: Avatar therapy versus treatment as usual, Outcome 2: Mental state:
1b. Specific – insight – average endpoint score (BAVQ-R attitude to voices, high = poor) – short term
Study or Subgroup
NCT03148639
















IV, Fixed, 95% CI
-5.97 [-10.98 , -0.96]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours avatar therapy Favours treatment as usual
 
 
Analysis 1.3.   Comparison 1: Avatar therapy versus treatment as usual, Outcome 3: Mental state: 1c. Specific
– insight – average endpoint score (BAVQ-R attitude to voices, high = poor, skewed data) – short term
 
Mental state: 1c. Specific – insight – average endpoint score (BAVQ-R attitude to voices, high = poor, skewed data) – short term
Study Intervention Mean SD n
Avatar therapy 18.88 7.24 14Le9 2013
Treatment as usual 12.37 12.61 12
 
 
Analysis 1.4.   Comparison 1: Avatar therapy versus treatment as usual, Outcome 4: Mental state: 1d.
Specific – depression – average endpoint score (various scales, high = poor, skewed data – short term
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Mental state: 1d. Specific – depression – average endpoint score (various scales, high = poor, skewed data – short term
Study Intervention Mean SD n
BDI
Avatar therapy 11.13 13.77 12NCT03148639
Standard care 25.43 8.48 7
CDS
Avatar therapy 8.5 5.29 14Le9 2013
Treatment as usual 4 1.41 12
 
 
Analysis 1.5.   Comparison 1: Avatar therapy versus treatment as usual, Outcome 5: Mental
state: 1e. Specific – negative – average endpoint score (PANSS-N, high = poor) – short term
Study or Subgroup
NCT03148639
















IV, Fixed, 95% CI
-1.17 [-5.70 , 3.36]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours avatar therapy Favours treatment as usual
 
 
Analysis 1.6.   Comparison 1: Avatar therapy versus treatment as usual, Outcome 6: Mental





Test for overall effect: Z = 1.38 (P = 0.17)





















IV, Fixed, 95% CI
-8.07 [-19.49 , 3.35]
-8.07 [-19.49 , 3.35]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours avatar therapy Favours treatment as usual
 
 
Analysis 1.7.   Comparison 1: Avatar therapy versus treatment as usual, Outcome 7: Mental





Test for overall effect: Z = 2.97 (P = 0.003)





















IV, Fixed, 95% CI
-5.51 [-9.15 , -1.87]
-5.51 [-9.15 , -1.87]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours avatar therapy Favours treatment as usual
 
 
Analysis 1.8.   Comparison 1: Avatar therapy versus treatment as usual, Outcome 8: Mental
state: 2c. General – total – average endpoint score (PSRS, high poor, skewed data) – short term
 
Mental state: 2c. General – total – average endpoint score (PSRS, high poor, skewed data) – short term
Study Intervention Mean SD n
Avatar therapy 23.63 8.03 14Le9 2013
Treatment as usual 20 13.1 12
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Analysis 1.9.   Comparison 1: Avatar therapy versus treatment as usual, Outcome






Test for overall effect: Z = 0.39 (P = 0.70)



















M-H, Fixed, 95% CI
1.85 [0.09 , 40.05]
1.85 [0.09 , 40.05]
Risk Ratio
M-H, Fixed, 95% CI
0.002 0.1 1 10 500
Favours avatar therapy Favours treatment as usual
 
 
Analysis 1.10.   Comparison 1: Avatar therapy versus treatment as usual,






Test for overall effect: Z = 0.00 (P = 1.00)



















M-H, Fixed, 95% CI
0.00 [-0.20 , 0.20]
0.00 [-0.20 , 0.20]
Risk Difference
M-H, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours avatar therapy Favours treatment as usual
 
 
Analysis 1.11.   Comparison 1: Avatar therapy versus treatment as






Test for overall effect: Z = 1.71 (P = 0.09)



















M-H, Fixed, 95% CI
11.27 [0.70 , 181.41]
11.27 [0.70 , 181.41]
Risk Ratio
M-H, Fixed, 95% CI
0.002 0.1 1 10 500
Favours avatar therapy Favours treatment as usual
 
 
Avatar Therapy for people with schizophrenia or related disorders (Review)









Cochrane Database of Systematic Reviews
Analysis 1.12.   Comparison 1: Avatar therapy versus treatment as usual,
Outcome 12: Leaving study early: 2. For specific reason – short term
Study or Subgroup





Test for overall effect: Z = 0.60 (P = 0.55)





Test for overall effect: Z = 1.58 (P = 0.11)





























M-H, Fixed, 95% CI
2.60 [0.12 , 58.48]
2.60 [0.12 , 58.48]
9.53 [0.58 , 156.49]
9.53 [0.58 , 156.49]
Risk Ratio
M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours avatar therapy Favours treatment as usual
 
 
Analysis 1.13.   Comparison 1: Avatar therapy versus treatment
as usual, Outcome 13: Adverse e9ects: anxiety – short term
Study or Subgroup











Test for overall effect: Not applicable



























M-H, Fixed, 95% CI
5.54 [0.34 , 89.80]




M-H, Fixed, 95% CI
0.001 0.1 1 10 1000
Favours avatar therapy Favours treatment as usual
 
 
Analysis 1.14.   Comparison 1: Avatar therapy versus treatment as usual, Outcome





Test for overall effect: Z = 3.21 (P = 0.001)





















IV, Fixed, 95% CI
9.99 [3.89 , 16.09]
9.99 [3.89 , 16.09]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours avatar therapy Favours treatment as usual
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Comparison 2.   Avatar therapy versus supportive counselling





Statistical method Effect size
2.1 Mental state: 1a. Specific – positive – av-
erage endpoint score (SAPS, high = poor,
skewed data) – short term
1   Other data No numeric data
2.2 Mental state: 1b. Specific – insight – av-
erage endpoint score (various scales, high =
poor) – short term
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.2.1 Attitude to voices (BAVQ-R) 1 124 Mean Difference (IV, Fixed, 95% CI) -8.39 [-14.31, -2.47]
2.2.2 Acceptance of voice (VAAS) 1 124 Mean Difference (IV, Fixed, 95% CI) 4.73 [1.40, 8.06]
2.2.3 Power of voice (VPDS) 1 115 Mean Difference (IV, Fixed, 95% CI) -0.36 [-0.89, 0.17]
2.2.4 Total (VAAS) 1 115 Mean Difference (IV, Fixed, 95% CI) -2.91 [-5.71, -0.11]
2.3 Mental state: 1c. Specific – depression –
average endpoint score (various scales, high
= poor, skewed data) – short term
1   Other data No numeric data
2.3.1 CDS 1   Other data No numeric data
2.3.2 DASS-21 total 1   Other data No numeric data
2.4 Mental state: 1d. Specific – negative – av-
erage endpoint score (SANS, high = good,
skewed data) – short term
1   Other data No numeric data
2.5 Mental state: 2a. General – average end-
point score ( PSYRATS total, high = poor) –
short term
1 124 Mean Difference (IV, Fixed, 95% CI) -4.74 [-8.01, -1.47]
2.6 Leaving study early: 1a. For any reason –
short term
1 150 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.59, 1.89]
2.7 Leaving study early: 1b. For specific rea-
son – short term
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.7.1 Not contactable 1 150 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.63, 14.39]
2.7.2 Refused 1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.38, 1.81]
2.7.3 Unwell 1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.11, 3.88]
2.7.4 Attended no sessions 1 150 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.13, 0.87]
2.7.5 Discontinued during early sessions (1-
6)
1 150 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [0.83, 3.47]
2.8 Quality of life: average endpoint score
(various scales, high = good) – short term
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
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Statistical method Effect size
2.8.1 MANSA 1 120 Mean Difference (IV, Fixed, 95% CI) 2.69 [-1.48, 6.86]
2.8.2 Rosenberg Self-Esteem Scale 1 121 Mean Difference (IV, Fixed, 95% CI) 0.55 [-1.55, 2.65]
 
 
Analysis 2.1.   Comparison 2: Avatar therapy versus supportive counselling, Outcome 1: Mental
state: 1a. Specific – positive – average endpoint score (SAPS, high = poor, skewed data) – short term
 
Mental state: 1a. Specific – positive – average endpoint score (SAPS, high = poor, skewed data) – short term
Study Intervention Mean SD n
Avatar therapy 32.1 20.5 62ISRCTN65314790
Treatment as usual 39.93 20.75 61
 
 
Analysis 2.2.   Comparison 2: Avatar therapy versus supportive counselling, Outcome 2: Mental
state: 1b. Specific – insight – average endpoint score (various scales, high = poor) – short term
Study or Subgroup




Test for overall effect: Z = 2.78 (P = 0.005)




Test for overall effect: Z = 2.79 (P = 0.005)









Test for overall effect: Z = 2.03 (P = 0.04)



















































IV, Fixed, 95% CI
-8.39 [-14.31 , -2.47]
-8.39 [-14.31 , -2.47]
4.73 [1.40 , 8.06]
4.73 [1.40 , 8.06]
-0.36 [-0.89 , 0.17]
-0.36 [-0.89 , 0.17]
-2.91 [-5.71 , -0.11]
-2.91 [-5.71 , -0.11]
Mean Difference
IV, Fixed, 95% CI
-4 -2 0 2 4
Favours avatar therapy Favours treatment as usual
 
 
Analysis 2.3.   Comparison 2: Avatar therapy versus supportive counselling, Outcome 3: Mental state: 1c.
Specific – depression – average endpoint score (various scales, high = poor, skewed data) – short term
 
Mental state: 1c. Specific – depression – average endpoint score (various scales, high = poor, skewed data) – short term
Study Intervention Mean SD n
CDS
ISRCTN65314790 Avatar therapy 5.43 5.2 63
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Treatment as usual 7.41 4.82 61
DASS-21 total
Avatar therapy 19.46 14.08 62ISRCTN65314790
Treatment as usual 22.63 15.52 61
 
 
Analysis 2.4.   Comparison 2: Avatar therapy versus supportive counselling, Outcome 4: Mental state:
1d. Specific – negative – average endpoint score (SANS, high = good, skewed data) – short term
 
Mental state: 1d. Specific – negative – average endpoint score (SANS, high = good, skewed data) – short term
Study Intervention Mean SD N
Avatar Therapy 26.67 19.79 63ISRCTN65314790
Supportive counselling 25.61 17.66 —
 
 
Analysis 2.5.   Comparison 2: Avatar therapy versus supportive counselling, Outcome 5:





Test for overall effect: Z = 2.84 (P = 0.005)





















IV, Fixed, 95% CI
-4.74 [-8.01 , -1.47]
-4.74 [-8.01 , -1.47]
Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
Favours avatar therapy Favours treatment as usual
 
 
Analysis 2.6.   Comparison 2: Avatar therapy versus supportive counselling,






Test for overall effect: Z = 0.19 (P = 0.85)



















M-H, Fixed, 95% CI
1.06 [0.59 , 1.89]
1.06 [0.59 , 1.89]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours avatar therapy Favours treatment as usual
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Analysis 2.7.   Comparison 2: Avatar therapy versus supportive counselling,



















Test for overall effect: Z = 0.45 (P = 0.65)





Test for overall effect: Z = 2.24 (P = 0.02)





Test for overall effect: Z = 1.46 (P = 0.14)



























































M-H, Fixed, 95% CI
3.00 [0.63 , 14.39]
3.00 [0.63 , 14.39]
0.83 [0.38 , 1.81]
0.83 [0.38 , 1.81]
0.67 [0.11 , 3.88]
0.67 [0.11 , 3.88]
0.33 [0.13 , 0.87]
0.33 [0.13 , 0.87]
1.70 [0.83 , 3.47]
1.70 [0.83 , 3.47]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours avatar therapy Favours treatment as usual
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Analysis 2.8.   Comparison 2: Avatar therapy versus supportive counselling, Outcome






Test for overall effect: Z = 1.26 (P = 0.21)




Test for overall effect: Z = 0.51 (P = 0.61)































IV, Fixed, 95% CI
2.69 [-1.48 , 6.86]
2.69 [-1.48 , 6.86]
0.55 [-1.55 , 2.65]
0.55 [-1.55 , 2.65]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours avatar therapy Favours treatment as usual
 
 
A D D I T I O N A L   T A B L E S
 
Methods Allocation: randomised (clearly described)
Blinding: single blind (outcomes assessor)
Duration: minimum 1 year
Design: parallel, crossover
Setting: outpatient and inpatient settings
Participants Diagnosis: people with a clinical diagnosis of schizophrenia using DSM-IV criteria
History: adults randomised from waiting list and referred to research staH
N= 300
Age: ≥ 18 years
Sex: men and women
Inclusion criteria: DSM-IV diagnosis of schizophrenia, age ≥ 18 years
Exclusion criteria: any other disease or alcohol and drug problem
Interventions 1. Avatar Therapy. N= 150
Programme for 12 weeks, once a week, follow-up at 6 months and 1 year
2. Waiting list. N= 150
They will receive Avatar Therapy sessions after phase one is finished.
Outcomes Mental state (binary outcomes)
Relapses (binary outcomes)
Quality of life (binary outcomes)
Costs: cost of services, cost of care
Table 1.   Design of a future study 
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Adverse events related to yoga (number and type of injuries)
Service outcomes: days in hospital, time attending outpatient psychiatric clinic
Notes Adherence should be logged with participants expected to adhere to 70–75% of scheduled ses-
sions.
Table 1.   Design of a future study  (Continued)
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; n: number of participants.
 
H I S T O R Y
Protocol first published: Issue 9, 2015
Review first published: Issue 5, 2020
C O N T R I B U T I O N S   O F   A U T H O R S
GA: data extraction, data entry, review writing and data analyses.
TK: data extraction, data entry.
FS: protocol development, search, screening and final check before submission.




S O U R C E S   O F   S U P P O R T
Internal sources
• No source of support, Other
External sources
• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. General
Since protocol publication (Moazzen 2015), we have updated the methods section of the review using the latest template provided by
Cochrane Schizophrenia Group. These amendments, slightly aHected the review criteria and objectives.
2. Specific
2.1. Objectives
We have altered the wording of the objectives to more accurately reflect the review title.
2.2. Types of outcome measures
We have made changes to the layout and format of Types of outcome measures in line with latest Cochrane Schizophrenia Group
presentation of outcomes.
For example – significant response is now clinically important change.
There were too many mental state outcomes listed as primary outcomes in the protocol. We have specified two (positive symptoms and
insight) and added at least one adverse eHect, in line with MECIR requirements to include an adverse eHect outcome in primary outcomes.
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2.3. Summary of findings outcomes
There were only five SOF outcomes in the protocol. We have added two further outcomes to the 'Summary of findings' tables (adverse
eHects and leaving the study early).
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